[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 239
1. Bortolin MT, Zanussi S, Talamini R, Simonelli C, Pratesi C, Tedeschi R, Abbruzzese L, Manuele R, Rupolo M, Tirelli U, De Paoli P: Predictive value of HIV type 1 DNA levels on overall survival in HIV-related lymphoma Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT). AIDS Res Hum Retroviruses; 2010 Feb;26(2):245-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of HIV type 1 DNA levels on overall survival in HIV-related lymphoma Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT).
  • The kinetics and predictive value of HIV-1 DNA (HIV DNA) levels in relapsed or refractory HIV lymphoma patients, treated with high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT), were investigated.
  • HIV DNA was measured by real-time PCR in the peripheral blood mononuclear cells (PBMCs) of 22 patients observed for a median follow-up of 31.0 months.
  • At baseline, HIV DNA was found to be correlated with HIV-1 RNA (HIV RNA) (r = 0.56), but not with CD4(+) counts (r = -0.10).
  • HIV RNA load was under control for the entire follow-up, while HIV DNA levels were almost always detectable (baseline levels vs. 1 year from ASCT levels, p > 0.05).
  • Baseline HIV DNA levels were significantly different between alive and deceased patients (p = 0.03), and the overall survival (OS) analysis showed that for patients with higher HIV DNA levels at baseline there was a higher and nearly significant risk of death if compared to patients with lower levels (HR, 8.33, 95% CI, 0.99-70.06, p = 0.05).
  • Our study demonstrated that high HIV DNA levels at baseline could predict overall survival after ASCT in one of the largest cohorts of HIV lymphoma patients treated with salvage therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. DNA, Viral / blood. HIV-1 / isolation & purification. Lymphoma, AIDS-Related / mortality. Stem Cell Transplantation. Viral Load


2. Vega F, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, Finch CJ, Vilchez RA, McGregor D, Jorgensen JL: Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol; 2005 Jun;18(6):806-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles.
  • Plasmablastic lymphoma is an aggressive neoplasm that shares many cytomorphologic and immunophenotypic features with plasmablastic plasma cell myeloma.
  • However, plasmablastic lymphoma is listed in the World Health Organization (WHO) classification as a variant of diffuse large B-cell lymphoma.
  • To characterize the relationship between plasmablastic lymphoma and plasmablastic plasma cell myeloma, we performed immunohistochemistry using a large panel of B-cell and plasma cell markers on nine cases of plasmablastic lymphoma and seven cases of plasmablastic plasma cell myeloma with and without HIV/AIDS.
  • All cases of plasmablastic lymphoma and plasmablastic plasma cell myeloma were positive for MUM1/IRF4, CD138, and CD38, and negative for CD20, corresponding to a plasma cell immunophenotype.
  • PAX-5 and BCL-6 were weakly positive in 2/9 and 1/5 plasmablastic lymphomas, and negative in all plasmablastic plasma cell myelomas.
  • Three markers that are often aberrantly expressed in cases of plasma cell myelomas, CD56, CD4 and CD10, were positive in 5/9, 2/5, and 6/9 plasmablastic lymphomas, and in 3/7, 1/5, and 2/7 plasmablastic plasma cell myelomas.
  • The only significant difference between plasmablastic lymphoma and plasma cell myeloma was the presence of EBV-encoded RNA, which was positive in all plasmablastic lymphoma cases tested and negative in all plasma cell myelomas.
  • In conclusion, most cases of AIDS-related plasmablastic lymphoma have an immunophenotype and tumor suppressor gene expression profile virtually identical to plasmablastic plasma cell myeloma, and unlike diffuse large B-cell lymphoma.
  • These results do not support the suggestion in the WHO classification that plasmablastic lymphoma is a variant of diffuse large B-cell lymphoma.
  • [MeSH-major] Immunophenotyping. Lymphoma / pathology. Multiple Myeloma / pathology. Plasma Cells / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / analysis. DNA, Viral / genetics. DNA-Binding Proteins / analysis. Epstein-Barr Virus Infections / immunology. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / virology. Female. Herpesvirus 4, Human / genetics. Herpesvirus 8, Human / genetics. Humans. Immunohistochemistry. In Situ Hybridization. Ki-67 Antigen / analysis. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / pathology. Lymphoma, AIDS-Related / virology. Male. Middle Aged. Polymerase Chain Reaction. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6. Transcription Factors / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Mod Pathol. 2005 Jun;18(6):873. Medeiros, Leonard J [corrected to Medeiros, L Jeffrey]
  • (PMID = 15578069.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


3. Navarro JT, Hernández A, Rodríguez-Manzano J, Mate JL, Grau J, Morgades M, Martró E, Tural C, Ribera JM, Matas L: Plasma Epstein-Barr viral load measurement as a diagnostic marker of lymphoma in HIV-infected patients. Med Clin (Barc); 2010 Oct 9;135(11):485-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma Epstein-Barr viral load measurement as a diagnostic marker of lymphoma in HIV-infected patients.
  • BACKGROUND AND OBJECTIVES: To assess the use of the Epstein-Barr virus (EBV) viral load as a marker for lymphoma diagnosis in HIV-infected patients.
  • We also aimed to identify the relationship between EBV viral load in plasma and the presence of EBV in lymphoma cells.
  • PATIENTS AND METHODS: Retrospective observational study of two HIV-infected populations: one of patients diagnosed with lymphoma and a control group.
  • Thirty-nine patients with AIDS-related lymphoma (ARL) (32 non-Hodgkin's and 7 Hodgkin's lymphomas) and 134 HIV-positive individuals without neoplasia or opportunistic infections were studied.
  • Blood samples were collected before lymphoma treatment in ARL patients.
  • EBV viral load was measured in plasma by real-time quantitative PCR and the presence of EBV-EBER mRNA in lymphoma tumor was investigated by in situ hybridization.
  • RESULTS: Patients with ARL had higher EBV viral loads than those without lymphoma: 24,180.5 (±73,387.6)copies/mL versus 2.6 (±21.6)copies/mL (p<0.001).
  • HIV-infected patients without lymphoma had negative or very low EBV load values.
  • Among ARL patients, no correlation was found between EBV viral loads and CD4+ lymphocyte counts or between EBV and HIV RNA loads, or any other clinical or biological parameter.
  • Cases with an EBV-EBER-positive lymphoma had higher EBV viral loads than those with EBER-negative tumors.
  • CONCLUSIONS: EBV viral load is a useful marker of lymphoma in HIV-infected patients, and may be a useful tool for early diagnosis and treatment.
  • [MeSH-major] Herpesvirus 4, Human. Lymphoma, AIDS-Related / blood. Lymphoma, AIDS-Related / diagnosis. Viral Load

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 20673682.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


Advertisement
4. Lan K, Murakami M, Bajaj B, Kaul R, He Z, Gan R, Feldman M, Robertson ES: Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor. Cancer Biol Ther; 2009 Nov;8(22):2136-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor.
  • Primary effusion lymphoma (PEL) is a common cancer in AIDS patients closely associated with Kaposi's sarcoma-associated herpesvirus (KSHV).
  • Previously, we showed that KSHV latency associated nuclear antigen (LANA) stabilizes intracellular activated Notch1 (ICN) involved in maintenance of the malignant phenotype of KSHV infected PEL cells in vitro.
  • In contrast, GSI had no effect on mice harboring BJAB cells, a KSHV negative Burkitt's lymphoma cell line where ICN levels were negligible.
  • Our study provides further evidence to suggest that targeted downregulation of abnormal Notch signaling has therapeutic potential for KSHV related primary effusion lymphomas.
  • [MeSH-major] Amyloid Precursor Protein Secretases / antagonists & inhibitors. Dipeptides / therapeutic use. Herpesviridae Infections. Herpesvirus 8, Human / pathogenicity. Lymphoma, Primary Effusion / drug therapy. Neoplasm Proteins / antagonists & inhibitors. Receptor, Notch1 / antagonists & inhibitors. Tumor Virus Infections
  • [MeSH-minor] Animals. Antigens, Viral / physiology. Apoptosis. Burkitt Lymphoma / pathology. Cell Line, Tumor / transplantation. Herpesvirus 4, Human / isolation & purification. Herpesvirus 4, Human / pathogenicity. Mice. Mice, Inbred NOD. Mice, SCID. Necrosis. Nuclear Proteins / physiology. Random Allocation. Signal Transduction / drug effects. Specific Pathogen-Free Organisms. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2009 Nov;8(22):2144-6 [20068386.001]
  • (PMID = 19783901.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / PHS HHS / / A1067037; United States / NCI NIH HHS / CA / CA091792; United States / NCI NIH HHS / CA / CA108461; United States / NIDCR NIH HHS / DE / DE017338
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Dipeptides; 0 / N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; 0 / Neoplasm Proteins; 0 / Notch1 protein, mouse; 0 / Nuclear Proteins; 0 / Receptor, Notch1; 0 / latency-associated nuclear antigen; EC 3.4.- / Amyloid Precursor Protein Secretases
  •  go-up   go-down


5. Ho SF, Fink C, Murray PI: Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for AIDS-associated lymphoma. Ocul Immunol Inflamm; 2005 Dec;13(6):471-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for AIDS-associated lymphoma.
  • We report an HIV-positive patient who developed a unilateral retinitis and subsequent intracranial lesions.
  • The finding of Epstein Barr virus (EBV) DNA at a > 1-log greater concentration in the vitreous compared to blood raised the possibility of a primary CNS non-Hodgkin's lymphoma, which was subsequently confirmed on brain biopsy.
  • [MeSH-major] DNA, Viral / genetics. Herpesvirus 4, Human / genetics. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321894.001).
  • [ISSN] 0927-3948
  • [Journal-full-title] Ocular immunology and inflammation
  • [ISO-abbreviation] Ocul. Immunol. Inflamm.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


6. Jabri L: [Lymphomas and HIV: updates]. Ann Pathol; 2008 Nov;28 Spec No 1(1):S114-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphomas and HIV: updates].
  • [Transliterated title] Lymphomes et VIH : actualités.
  • [MeSH-major] Lymphoma, AIDS-Related

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18984285.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 19
  •  go-up   go-down


7. Corti M, Villafañe MF, Trione N, Schtirbu R, Narbaitz M: Primary pulmonary AIDS-related lymphoma. Rev Inst Med Trop Sao Paulo; 2005 Jul-Aug;47(4):231-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary AIDS-related lymphoma.
  • Extranodal involvement is common in lymphomas associated with human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS).
  • However, primary pulmonary AIDS-related non-Hodgkin's lymphoma is very rare and only few reports were published in the medical literature.
  • Primary pulmonary lymphoma associated with AIDS is generally a high-grade B-cell non-Hodgkin lymphoma and Epstein-Barr virus is strongly associated with the pathogenesis of these tumors.
  • We report a patient with AIDS and primary pulmonary lymphoma which clinical presentation was a total atelectasis of the left lung.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Pulmonary Atelectasis / etiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16138208.001).
  • [ISSN] 0036-4665
  • [Journal-full-title] Revista do Instituto de Medicina Tropical de São Paulo
  • [ISO-abbreviation] Rev. Inst. Med. Trop. Sao Paulo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


8. Leiggener CS, Kunz Ch, Lohri A, Fridrich K, Honigmann K: [HIV-associated lymphoma -- an unusual cause of pathological mandibular fracture]. Mund Kiefer Gesichtschir; 2005 Jan;9(1):48-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HIV-associated lymphoma -- an unusual cause of pathological mandibular fracture].
  • [Transliterated title] HIV-assoziiertes Lymphom -- ungewöhnliche Ursache einer pathologischen Unterkieferfraktur. Fallbericht und Behandlungsoptionen bei Immundefizienz.
  • Despite the introduction of highly active antiretroviral therapy (HAART), diffuse large B-cell lymphoma (DLBCL) remains a common malignancy in human immunodeficiency virus (HIV)-infected patients, especially the plasmablastic variant.
  • About 50% of lymphomas in HIV patients are extranodal and half of them occur in the head and neck area.
  • We report the case of a 52-year-old patient with a known HIV infection and fracture of the angular region of the mandible.
  • A biopsy performed at the time of revision revealed the diagnosis of a primary lymphoma in the mandible.
  • After chemotherapy had induced complete remission of the lymphoma and autogenous iliac crest bone grafting had been performed the fracture united.
  • Primary lymphoma in the mandible is a disease that presents with a nonspecific radiological appearance which may mimic osteomyelitis or periodontal pathology.
  • In our experience HIV-positive patients with mandibular fracture should be treated according to the guidelines established for HIV-negative patients.
  • [MeSH-major] Fractures, Spontaneous / diagnosis. Lymphoma, AIDS-Related / diagnosis. Mandibular Fractures / diagnosis. Mandibular Neoplasms / diagnosis

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):347-8 [12626898.001]
  • [Cites] Am J Otolaryngol. 2000 Jan-Feb;21(1):10-3 [10668671.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Aug;55(8):853-6 [9251616.001]
  • [Cites] J Craniomaxillofac Surg. 1992 Oct;20(7):297-302 [1401107.001]
  • [Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]
  • [Cites] J Oral Maxillofac Surg. 1995 Oct;53(10):1134-9 [7562164.001]
  • [Cites] J Oral Maxillofac Surg. 1990 Apr;48(4):409-15 [2179495.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Plast Reconstr Surg. 1993 Apr;91(4):577-80 [8446709.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1993 Sep;76(3):272-5 [8378039.001]
  • [Cites] Br J Oral Maxillofac Surg. 2000 Aug;38(4):397 [10922171.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Mar;106(3):258-60 [1589218.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):354-9 [11555712.001]
  • [Cites] Laryngoscope. 1995 Apr;105(4 Pt 2 Suppl 68):1-18 [7715397.001]
  • [Cites] Mund Kiefer Gesichtschir. 2001 Jul;5(4):227-32 [11550605.001]
  • (PMID = 15688241.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Mani D, Dorer RK, Aboulafia DM: Therapy-related acute myeloid leukemia following HIV-associated lymphoma. Clin Lymphoma Myeloma; 2009 Aug;9(4):316-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myeloid leukemia following HIV-associated lymphoma.
  • In the highly active antiretroviral therapy era, an increasingly large number of HIV-infected patients are developing non- AIDS-defining cancers (NADCs).
  • As patients survive longer, long-term therapy-related complications take on greater importance.
  • Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.
  • With the diagnosis of therapy-related acute myeloid leukemia (AML) secured, he began induction chemotherapy with idarubicin and cytarabine.
  • Through a literature search, we were able to identify 4 additional cases of therapy-related AML in AIDS patients following chemotherapy for lymphomas.
  • The median age of these patients at the time of AML diagnosis was 39 years (range, 33-59 years), the median time from the treatment of lymphoma to AML was 18 months (range, 11-48 months), and the median survival following induction chemotherapy was 4 weeks (range, 2-16 weeks).
  • With many HIV-infected patients surviving alkylator and topoisomerase inhibitor-based treatment and radiation therapy for AIDS-defining cancers and NADCs, long-term follow-up for therapy-related complications assumes greater importance.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19717383.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


10. Miyake A, Dewan MZ, Ishida T, Watanabe M, Honda M, Sata T, Yamamoto N, Umezawa K, Watanabe T, Horie R: Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ. Microbes Infect; 2008 Jun;10(7):748-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr virus (EBV) causes EBV-associated lymphoproliferative diseases in patients with profound immune suppression.
  • Most of these diseases are life-threatening and the prognosis of AIDS-associated lymphomas is extremely unfavorable.
  • We investigated the possibility of nuclear factor kappa B (NF-kappaB) inhibition by dehydroxymethylepoxyquinomicin (DHMEQ) for the treatment and prevention of EBV-associated lymphoproliferative diseases.
  • These results suggest that NF-kappaB is a molecular target for the treatment and prevention of EBV-associated lymphoproliferative diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538617.001).
  • [ISSN] 1286-4579
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Cyclohexanones; 0 / Immunologic Factors; 0 / NF-kappa B; 0 / dehydroxymethylepoxyquinomicin
  •  go-up   go-down


11. Epeldegui M, Widney DP, Martínez-Maza O: Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol; 2006 Sep;18(5):444-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions.
  • PURPOSE OF REVIEW: We discuss recently published studies that elucidate the pathogenesis of AIDS-associated lymphoma.
  • RECENT FINDINGS: Several recent reports have provided valuable new information on the role of gamma-herpesviruses in the pathogenesis of AIDS-associated lymphoma.
  • In addition to this, significant new information has become available on how B cell activation-associated DNA-modifying events, involving activation-induced cytidine deaminase and DNA polymerase-eta, contribute to the molecular lesions that result in AIDS-associated lymphoma.
  • In particular, new evidence that oncogenic viruses can directly induce activation-induced cytidine deaminase expression and oncogene mutation in human B cells is of central relevance to better understanding the pathogenesis of AIDS-associated lymphoma.
  • SUMMARY: New information provides insights into the contributions of immune dysfunction and oncogenic virus infection to pathogenesis of AIDS-associated lymphoma, and may lead to new potential targets for therapeutic intervention in these cancers.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / genetics. Lymphoma, AIDS-Related / virology. Lymphoma, B-Cell / genetics. Oncogenic Viruses / pathogenicity

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894291.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI35040; United States / NCI NIH HHS / CA / CA57152; United States / NCI NIH HHS / CA / CA70080; United States / NCI NIH HHS / CA / CA73475; United States / NCI NIH HHS / CA / CA96888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.7 / DNA-Directed DNA Polymerase; EC 2.7.7.7 / Rad30 protein; EC 3.5.4.5 / Cytidine Deaminase
  • [Number-of-references] 28
  •  go-up   go-down


12. Davis FS: Epidemiology of brain tumors. Expert Rev Anticancer Ther; 2007 Dec;7(12 Suppl):S3-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are few proven causes of brain tumors: high-dose ionizing radiation, inherited genetic syndromes and AIDs-related brain lymphomas.
  • [MeSH-major] Brain Neoplasms / epidemiology. Genetic Predisposition to Disease / epidemiology. Lymphoma, AIDS-Related / epidemiology. Radiation Injuries / epidemiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076316.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 104
  •  go-up   go-down


13. Nyagol J, De Falco G, Lazzi S, Luzzi A, Cerino G, Shaheen S, Palummo N, Bellan C, Spina D, Leoncini L: HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas. J Hematop; 2008 Jul;1(1):3-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas.
  • In some subtypes of non-Hodgkin's lymphomas, higher local vascular endothelial growth factor (VEGF) expression correlates with increased microvessel density.
  • Several studies have indicated that VEGF receptors are also targeted by Tat protein from the HIV-1-infected cells.
  • We evaluated the role of HIV-1 Tat in regulating the level of VEGF expression and microvessel density in the AIDS-related diffuse large B-cell (DLBCL) and Burkitt lymphomas (BL).
  • Reduced VEGF protein expression in primary HIV-1 positive BL and DLBCL, compared to the negative cases, supported the findings of promoter downregulation from the cell lines.
  • Microvascular density assessed by CD34 expression was, however, higher in HIV-1 positive than in HIV-1 negative tumors.
  • Thus, targeting Tat protein itself and stabilizing transient silencing of VEGF expression or use of monoclonal antibodies against their receptors in the AIDS-associated tumors will open a window for future explorable pathways in the management of angiogenic phenotypes in the AIDS-associated non-Hodgkin's lymphomas.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1996 Dec;2(12):1371-5 [8946838.001]
  • [Cites] Oncogene. 2000 Jan 20;19(3):373-9 [10656684.001]
  • [Cites] Oncogene. 1996 Jan 18;12(2):289-97 [8570206.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):66-70 [7596436.001]
  • [Cites] Leuk Lymphoma. 2007 Oct;48(10):2014-21 [17917969.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):223-30 [17595666.001]
  • [Cites] Exp Cell Res. 2007 May 1;313(8):1561-74 [17382929.001]
  • [Cites] Am J Pathol. 2007 Apr;170(4):1362-9 [17392174.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4647-52 [17360578.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Apr 13;355(3):693-9 [17320821.001]
  • [Cites] Nat Struct Mol Biol. 2007 Mar;14(3):249-50 [17293873.001]
  • [Cites] J Cell Biochem. 2007 Feb 15;100(3):727-37 [17115409.001]
  • [Cites] Curr Med Chem. 2006;13(16):1845-57 [16842197.001]
  • [Cites] FEBS J. 2005 Nov;272(22):5723-41 [16279938.001]
  • [Cites] Folia Histochem Cytobiol. 2004;42(4):241-3 [15704651.001]
  • [Cites] Biochem Pharmacol. 2004 Dec 15;68(12):2359-66 [15548382.001]
  • [Cites] Circulation. 1997 Dec 2;96(11):4083-94 [9403634.001]
  • [Cites] J Biol Chem. 1998 Nov 20;273(47):31119-24 [9813014.001]
  • [Cites] Science. 1998 Dec 4;282(5395):1837-9 [9874635.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3851-6 [9520456.001]
  • [Cites] J Clin Pathol. 1997 Jun;50(6):481-4 [9378813.001]
  • [Cites] Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):233-5 [7542074.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):3964-8 [7664263.001]
  • [Cites] Nature. 1994 Oct 20;371(6499):674-80 [7935812.001]
  • [Cites] Arch Orthop Trauma Surg. 2003 Nov;123(9):475-80 [12750926.001]
  • [Cites] Angiogenesis. 2002;5(3):141-51 [12831055.001]
  • [Cites] Cell Prolif. 2003 Jun;36(3):131-49 [12814430.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Curr Drug Targets Infect Disord. 2003 Jun;3(2):115-28 [12769789.001]
  • [Cites] J Rheumatol. 2003 Feb;30(2):260-8 [12563678.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]
  • [Cites] Hum Pathol. 2002 Jul;33(7):723-31 [12196924.001]
  • [Cites] Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44 [11965229.001]
  • [Cites] Clin Microbiol Rev. 2002 Apr;15(2):310-26 [11932235.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):838-45 [11764072.001]
  • [Cites] Biochem J. 2001 Feb 1;353(Pt 3):569-78 [11171054.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):462-8 [11212232.001]
  • [Cites] Curr Opin Oncol. 2000 Sep;12(5):445-9 [10975552.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):267-71 [10873597.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:3-10 [10804084.001]
  • [Cites] Am J Pathol. 1996 Apr;148(4):1065-74 [8644848.001]
  • (PMID = 19669199.001).
  • [ISSN] 1868-9256
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2712328
  •  go-up   go-down


14. Subirá D, Górgolas M, Castañón S, Serrano C, Román A, Rivas F, Tomás JF: Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients. HIV Med; 2005 Jan;6(1):21-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients.
  • BACKGROUND: Neurological disorders are common in HIV-infected patients.
  • Central nervous system (CNS) lymphoma should always be considered because it is an important cause of morbidity and mortality.
  • OBJECTIVES: To investigate the clinical utility of flow cytometry immunophenotyping (FCI) in diagnosing or discarding leptomeningeal involvement in HIV-infected patients and to compare its sensitivity with that of conventional cytological methods.
  • METHODS: Fifty-six cerebrospinal fluid (CSF) samples from 29 HIV-infected patients were independently evaluated by flow cytometry and cytology.
  • RESULTS: FCI and cytology gave concordant results for 48 of the 56 CSF samples studied: 37 were negative for malignancy and 11 had evidence of CNS lymphoma.
  • This advantage suggests that, in case of negative flow cytometry results, disorders other than non-Hodgkin's lymphoma should be strongly considered.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Meningeal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Burkitt Lymphoma / cerebrospinal fluid. Burkitt Lymphoma / diagnosis. Diagnosis, Differential. Female. Flow Cytometry / methods. Humans. Immunophenotyping / methods. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670248.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Carbone A, Gloghini A, Vaccher E, Marchetti G, Gaidano G, Tirelli U: KSHV/HHV-8 associated lymph node based lymphomas in HIV seronegative subjects. Report of two cases with anaplastic large cell morphology and plasmablastic immunophenotype. J Clin Pathol; 2005 Oct;58(10):1039-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KSHV/HHV-8 associated lymph node based lymphomas in HIV seronegative subjects. Report of two cases with anaplastic large cell morphology and plasmablastic immunophenotype.
  • BACKGROUND: Kaposi sarcoma associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) associated lymphomas, which often develop in human immunodeficiency virus (HIV) infected patients with advanced AIDS, present predominantly as primary effusion lymphoma (PEL) or, less frequently, as "solid" extracavitary based lymphomas, associated with serous effusions.
  • These last lymphomas, also called "solid PEL", have been reported before the development of an effusion lymphoma and after resolution of PEL.
  • Interestingly, KSHV/HHV-8 associated lymphomas that present as solid or extracavitary based lesions in HIV seropositive patients without serous effusions have been reported recently.
  • METHODS/RESULTS: This paper provides evidence for the existence of a previously undescribed KSHV/HHV-8 associated lymphoma in HIV seronegative patients without serous effusions.
  • These lymphomas exhibit a predilection for the lymph nodes and display anaplastic large cell morphology.
  • B and T cell associated antigens and other commonly used lymphoid markers were absent or weakly demonstrable in a fraction of the tumour cells.
  • CONCLUSIONS: Analysis of viral infection and immunohistological studies are of primary importance to define this lymph node based KSHV/HHV-8 associated lymphoma with anaplastic large cell morphology and plasmablastic immunophenotype occurring in HIV seronegative patients without serous effusions.
  • [MeSH-major] Herpesviridae Infections / complications. Herpesvirus 8, Human / isolation & purification. Lymphoma, Large B-Cell, Diffuse / virology
  • [MeSH-minor] Aged. Antigens, Neoplasm / analysis. HIV Seronegativity. Humans. Immunophenotyping. Male. Middle Aged

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Jan;13(1):77-85 [10658913.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]
  • [Cites] Leuk Lymphoma. 1999 Oct;35(3-4):379-87 [10706463.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):753-5 [10782162.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2069-73 [10979949.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):32-8 [11227070.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] AIDS Patient Care STDS. 2002 Apr;16(4):139-45 [12015867.001]
  • [Cites] Mod Pathol. 2003 May;16(5):424-9 [12748248.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):630 [12827623.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] J Clin Virol. 2003 Oct;28(2):155-64 [12957185.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):693-7 [15105661.001]
  • [Cites] Hum Pathol. 2004 May;35(5):632-5 [15138941.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] Cytokine Growth Factor Rev. 1997 Dec;8(4):293-312 [9620643.001]
  • [Cites] N Engl J Med. 1998 Aug 13;339(7):444-9 [9700178.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]
  • [Cites] Lab Invest. 1998 Dec;78(12):1637-42 [9881964.001]
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):165-74 [10343068.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):992-4 [10435572.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] Hum Pathol. 2002 Aug;33(8):846-9 [12203218.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1363-7 [12360052.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2002 Dec;21(12):831-44 [12525917.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] J Clin Pathol. 1994 May;47(5):418-22 [7517959.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):53-7 [8686762.001]
  • [Cites] Br J Haematol. 1996 Aug;94(2):318-23 [8759892.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] AIDS. 1996 Aug;10(9):941-9 [8853726.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3124-8 [8874212.001]
  • [Cites] Ann Intern Med. 1996 Nov 15;125(10):822-5 [8928989.001]
  • [Cites] J Infect Dis. 1997 May;175(5):1198-201 [9129085.001]
  • [Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]
  • [Cites] Int J Cancer. 1997 Oct 9;73(2):303-4 [9335459.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • (PMID = 16189148.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  • [Other-IDs] NLM/ PMC1770735
  •  go-up   go-down


16. Ho-Yen C, Chang F, van der Walt J, Lucas S: Gastrointestinal malignancies in HIV-infected or immunosuppressed patients: pathologic features and review of the literature. Adv Anat Pathol; 2007 Nov;14(6):431-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal malignancies in HIV-infected or immunosuppressed patients: pathologic features and review of the literature.
  • The gastrointestinal (GI) tract is a common internal organ to be involved by human immunodeficiency virus (HIV)-related malignancies.
  • It is the second most common site for Kaposi sarcoma after skin, and the commonest visceral site, for Kaposi sarcoma in AIDS patients.
  • GI lymphomas have been documented in approximately 25% of AIDS patients with systemic lymphomas.
  • Moreover, GI involvement of AIDS-lymphoma has been associated with poor prognosis and short survival.
  • Several other malignancies that occur in the GI tract are also closely related to HIV-infected or immunosuppressed individuals; these include posttransplant lymphoproliferative disorder, Epstein-Barr virus-associated smooth muscle tumors, anal precancerous lesions, and squamous cell carcinoma.
  • As a result of active antiretroviral therapy, patients infected with HIV are living longer and are consequently at increased risk for development of cancer.
  • Therefore, it is possible that the number of AIDS-associated malignancies will rise and the pattern of tumors may change in the future.
  • In this paper, the clinicopathologic features of GI malignancies associated with AIDS patients are reviewed and the differential diagnosis with other mimic lesions is discussed.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / pathology. Gastrointestinal Neoplasms / pathology. Immunocompromised Host. Immunosuppression. Lymphoma, AIDS-Related / pathology. Sarcoma, Kaposi / pathology


17. Deloose ST, Smit LA, Pals FT, Kersten MJ, van Noesel CJ, Pals ST: High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. Leukemia; 2005 May;19(5):851-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma.
  • Kaposi sarcoma-associated herpesvirus (KSHV) is known to be associated with two distinct lymphoproliferative disorders: primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD)/MCD-associated plasmablastic lymphoma.
  • We here report a high incidence of KSHV infection in solid HIV-associated immunoblastic/plasmablastic non-Hodgkin's lymphomas (NHLs), in patients lacking effusions and without evidence of (prior) MCD.
  • Within a cohort of 99 HIV-related NHLs, 10 cases were found to be KSHV positive on the basis of immunostaining for KSHV LNA-1 as well as KSHV-specific polymerase chain reaction.
  • Interestingly, all KSHV-positive cases belonged to a distinctive subgroup of 26 diffuse large B-cell lymphomas characterized by the expression of CD138 (syndecan-1) and plasmablastic/immunoblastic morphology.
  • These KSHV-positive lymphomas were preceded by Kaposi sarcoma in 60% of the patients and involved the gastrointestinal tract in 80%.
  • Our results indicate that KSHV infection is not restricted to PEL and MCD; it is also common (38%) in HIV-related solid immunoblastic/plasmablastic lymphomas.
  • [MeSH-major] Giant Lymph Node Hyperplasia / virology. HIV Infections / virology. Herpesviridae Infections / virology. Herpesvirus 8, Human. Lymphoma, AIDS-Related / virology. Lymphoma, Large B-Cell, Diffuse / virology. Sarcoma, Kaposi / virology


18. Yanagisawa Y, Sato Y, Asahi-Ozaki Y, Ito E, Honma R, Imai J, Kanno T, Kano M, Akiyama H, Sata T, Shinkai-Ouchi F, Yamakawa Y, Watanabe S, Katano H: Effusion and solid lymphomas have distinctive gene and protein expression profiles in an animal model of primary effusion lymphoma. J Pathol; 2006 Aug;209(4):464-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effusion and solid lymphomas have distinctive gene and protein expression profiles in an animal model of primary effusion lymphoma.
  • Lymphoma usually forms solid tumours in patients, and high expression levels of adhesion molecules are observed in these tumours.
  • However, Kaposi's sarcoma-associated herpesvirus (KSHV)-related primary effusion lymphoma (PEL) does not form solid tumours and adhesion molecule expression is suppressed in the cells.
  • Inoculation of a KSHV-associated PEL cell line into the peritoneal cavity of severe combined immunodeficiency mice resulted in the formation of effusion and solid lymphomas in the peritoneal cavity.
  • Proteomics using two-dimensional difference gel electrophoresis and DNA microarray analyses identified 14 proteins and 105 genes, respectively, whose expression differed significantly between effusion and solid lymphomas.
  • Five genes were identified as having similar expression profiles to that of lymphocyte function-associated antigen 1, an important adhesion molecule in leukocytes.
  • Among these, coronin 1A, an actin-binding protein, was identified as a molecule showing high expression in solid lymphoma by both DNA microarray and proteomics analyses.
  • Western and northern blotting showed that coronin 1A was predominantly expressed in solid lymphomas.
  • Moreover, KSHV-encoded lytic proteins, including viral interleukin-6, were highly expressed in effusion lymphoma compared with solid lymphoma.
  • These data demonstrate that effusion and solid lymphomas possess distinctive gene and protein expression profiles in our mouse model, and suggest that differences in gene and protein expression between effusion and solid lymphomas may be associated with the formation of effusion lymphoma or invasive features of solid lymphoma.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / virology. Gene Expression Regulation, Viral. Herpesvirus 8, Human. Lymphoma, AIDS-Related / genetics. Sarcoma, Kaposi / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. DNA, Viral / analysis. Electrophoresis, Gel, Two-Dimensional. Gene Expression Profiling. Humans. Lymphocyte Function-Associated Antigen-1 / genetics. Mice. Mice, SCID. Models, Animal. Oligonucleotide Array Sequence Analysis. Pleural Effusion, Malignant / metabolism. Pleural Effusion, Malignant / virology. Proteomics. Reverse Transcriptase Polymerase Chain Reaction. Viral Proteins / analysis


19. Nebuloni M, Cinque P, Sidenius N, Ferri A, Lauri E, Omodeo-Zorini E, Zerbi P, Vago L: Expression of the urokinase plasminogen activator receptor (uPAR) and its ligand (uPA) in brain tissues of human immunodeficiency virus patients with opportunistic cerebral diseases. J Neurovirol; 2009 Jan;15(1):99-107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously described uPAR/uPA overexpression in the cerebrospinal fluid (CSF) and brain tissues of patients with human immunodeficiency virus (HIV)-related cerebral diseases.
  • In this study, we examined uPAR/uPA expression by immunohistochemistry (IHC) in brains of HIV patients with opportunistic cerebral lesions and in HIV-positive/negative controls. uPAR was found in macrophages/microglia with the highest levels in cytomegalovirus (CMV) encephalitis, toxoplasmosis, and lymphomas; in cryptococcosis and progressive multifocal leukoencephalopathy (PML) cases, only a few positive cells were found and no positivity was observed in controls. uPA expression was demonstrated only in a few macrophages/microglia and lymphocytes in all the cases and HIV-positive controls without different pattern of distribution; no uPA immunostaining was found in cryptococcosis and HIV-negative controls.
  • [MeSH-major] AIDS-Related Opportunistic Infections / metabolism. Brain / metabolism. Brain Diseases / metabolism. Receptors, Urokinase Plasminogen Activator / biosynthesis. Urokinase-Type Plasminogen Activator / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2002 Nov 12;59(9):1350-5 [12427882.001]
  • [Cites] J Infect Dis. 2005 Mar 1;191(5):776-82 [15688295.001]
  • [Cites] J Cell Biol. 2007 Jun 4;177(5):927-39 [17548516.001]
  • [Cites] J Immunol. 2001 Jan 1;166(1):473-80 [11123326.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jun 8;284(2):346-51 [11394884.001]
  • [Cites] AIDS. 1998 Jul 30;12(11):1327-32 [9708412.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2001;:1-9 [11722975.001]
  • [Cites] J Neurovirol. 1999 Dec;5(6):659-69 [10602406.001]
  • [Cites] Brain Res. 2002 Feb 1;926(1-2):69-79 [11814408.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8862-7 [12084931.001]
  • [Cites] Scand J Immunol. 2005 Apr;61(4):347-56 [15853918.001]
  • [Cites] J Neuroimmunol. 2000 Nov 1;111(1-2):234-40 [11063844.001]
  • [Cites] Infect Immun. 2000 Apr;68(4):2156-60 [10722614.001]
  • [Cites] J Neurovirol. 2000 Feb;6(1):46-50 [10786996.001]
  • [Cites] Ann Neurol. 2004 May;55(5):687-94 [15122709.001]
  • [Cites] J Neuroimmunol. 2002 Aug;129(1-2):216-23 [12161038.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1359-64 [11818541.001]
  • [Cites] APMIS. 1999 Jan;107(1):160-7 [10190293.001]
  • [Cites] Scand J Infect Dis. 2004;36(1):14-9 [15000553.001]
  • [Cites] J Clin Pathol. 1997 Feb;50(2):157-60 [9155699.001]
  • [Cites] Immunobiology. 1998 Jul;199(1):152-62 [9717675.001]
  • [Cites] J Neuroinflammation. 2007 Jan 15;4:4 [17224051.001]
  • [Cites] J Clin Pathol. 1996 Jul;49(7):577-80 [8813958.001]
  • [Cites] Infect Immun. 2007 Aug;75(8):3848-58 [17517866.001]
  • [Cites] J Neuroimmunol. 2004 Dec;157(1-2):133-9 [15579290.001]
  • [Cites] Am J Clin Pathol. 1994 Dec;102(6):835-41 [7801901.001]
  • [Cites] Neurosci Lett. 2002 May 10;324(1):80-2 [11983300.001]
  • [Cites] Int J Oncol. 1999 Jan;14(1):169-74 [9863025.001]
  • [Cites] Brain. 2001 Oct;124(Pt 10):1978-88 [11571216.001]
  • (PMID = 19115132.001).
  • [ISSN] 1538-2443
  • [Journal-full-title] Journal of neurovirology
  • [ISO-abbreviation] J. Neurovirol.
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / 1R21 MH 075670-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands; 0 / Receptors, Urokinase Plasminogen Activator; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


20. Corti M, Carolis LD, Solari R, Villafañe MF, Schtirbu R, Lewi D, Narbaitz M: Non Hodgkin's lymphoma with cutaneous involvement in AIDS patients: report of five cases and review of the literature. Braz J Infect Dis; 2010 Jan-Feb;14(1):81-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non Hodgkin's lymphoma with cutaneous involvement in AIDS patients: report of five cases and review of the literature.
  • Cutaneous B cell lymphoma (CBCL) is a lymphoproliferative disorder of neoplastic B cell of the skin with a wide range of clinical manifestations.
  • Skin is one of the common sites for extra-nodal lymphomas in patients with AIDS and B cell type is less common than T cell type.
  • Only recently, the existence of B cell lymphomas presenting clinically in the skin without evidence of extra-cutaneous involvement has been accepted as primary CBCL.
  • Here, we are presenting 5 patients with cutaneous involvement in the setting of HIV/AIDS disease.
  • Two of them were primary cutaneous non-Hodgkin lymphomas.
  • All were CBCL; 3 were immunoblastic, 1 was plasmablastic, and the other was a Burkitt lymphoma.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428660.001).
  • [ISSN] 1678-4391
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Mani H, Jaffe ES: Hodgkin lymphoma: an update on its biology with new insights into classification. Clin Lymphoma Myeloma; 2009 Jun;9(3):206-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma: an update on its biology with new insights into classification.
  • In the past few years, there has been a greater understanding of the spectrum and biology of Hodgkin lymphoma (HL).
  • However, recent evidence suggests that CHL is not a single disease.
  • Nodular sclerosis HL might also be related to primary mediastinal B-cell lymphoma and mediastinal gray-zone lymphomas.
  • [MeSH-major] Hodgkin Disease / classification. Hodgkin Disease / diagnosis
  • [MeSH-minor] Adolescent. Adult. Apoptosis. Cytokines / metabolism. Female. Genetic Predisposition to Disease. HIV Infections / metabolism. Herpesvirus 4, Human / metabolism. Humans. Immunophenotyping. Lymphocytes / metabolism. Lymphoma, B-Cell / metabolism. Male. Social Class

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 1;94(9):3108-13 [10556196.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):387-94 [10637283.001]
  • [Cites] J Exp Med. 2004 Apr 19;199(8):1041-52 [15078899.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] J Natl Cancer Inst. 2004 May 19;96(10):780-4 [15150306.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):727-38 [15151213.001]
  • [Cites] Blood. 1999 Jul 15;94(2):411-6 [10397707.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3122-7 [10506608.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:184-202 [15561683.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Mar;37(3):511-7 [15618006.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):395-402 [10637284.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1443-50 [10666223.001]
  • [Cites] Blood. 2000 May 15;95(10):3020-4 [10807764.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1889-99 [10961891.001]
  • [Cites] Isr Med Assoc J. 2000 Jul;2(7):501-3 [10979320.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):262-9 [11091850.001]
  • [Cites] Blood. 2001 Jan 15;97(2):496-501 [11154228.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):297-306 [11224599.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):219-28 [11266530.001]
  • [Cites] Hematol Oncol. 2001 Mar;19(1):1-17 [11276042.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2080-4 [11280769.001]
  • [Cites] Blood. 2001 May 1;97(9):2798-807 [11313274.001]
  • [Cites] Histopathology. 2001 Apr;38(4):368-75 [11318902.001]
  • [Cites] Blood. 2001 May 15;97(10):3191-6 [11342448.001]
  • [Cites] Blood. 2001 Jul 1;98(1):194-200 [11418480.001]
  • [Cites] Blood. 2001 Aug 1;98(3):762-70 [11468177.001]
  • [Cites] Mol Med. 2001 May;7(5):285-92 [11474574.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1807-14 [11696441.001]
  • [Cites] Blood. 2002 Jan 1;99(1):258-67 [11756180.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):221-30 [11773173.001]
  • [Cites] Blood. 2002 Jan 15;99(2):618-26 [11781246.001]
  • [Cites] Blood. 2002 Jan 15;99(2):690-3 [11781255.001]
  • [Cites] Leuk Res. 2002 Mar;26(3):261-9 [11792415.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):585-96 [11839579.001]
  • [Cites] Curr Opin Immunol. 2002 Apr;14(2):216-23 [11869895.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3753-8 [12881319.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):767-77 [14608905.001]
  • [Cites] Mod Pathol. 2003 Nov;16(11):1141-7 [14614054.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1513-22 [14657710.001]
  • [Cites] Eur J Haematol. 2004 Jan;72(1):1-9 [14962256.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1755-62 [14604957.001]
  • [Cites] Hum Pathol. 2007 Jan;38(1):103-13 [16949642.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):875-9 [17131320.001]
  • [Cites] Adv Anat Pathol. 2007 May;14(3):189-94 [17452815.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2700-7 [17119127.001]
  • [Cites] Hematol Oncol. 2004 Mar;22(1):11-26 [15152367.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):609-11 [15160926.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1236-43 [15247136.001]
  • [Cites] Acta Haematol. 2004;112(3):129-35 [15345894.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1375-84 [15359636.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1551-7 [15370206.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1063-83 [5947336.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1189-201 [5329907.001]
  • [Cites] Bull Hist Med. 1969 Mar-Apr;43(2):138-75 [4890530.001]
  • [Cites] Bull N Y Acad Med. 1970 Jan;46(1):67-9 [4903331.001]
  • [Cites] Int J Cancer. 1971 Sep 15;8(2):192-201 [5133848.001]
  • [Cites] N Engl J Med. 1977 Feb 3;296(5):248-50 [831107.001]
  • [Cites] Am J Pathol. 1977 Apr;87(1):19-32 [322504.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1979;31(3):211-25 [43015.001]
  • [Cites] Ann Intern Med. 1980 May;92(5):587-95 [6892984.001]
  • [Cites] N Engl J Med. 1981 Jan 15;304(3):135-40 [6255329.001]
  • [Cites] Immunol Rev. 1983;70:167-92 [6403456.001]
  • [Cites] Br J Cancer. 1983 May;47(5):707-12 [6849804.001]
  • [Cites] Am J Clin Pathol. 1984 Dec;82(6):666-73 [6391148.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):599-606 [3041849.001]
  • [Cites] Cancer. 1989 Mar 15;63(6):1150-3 [2917317.001]
  • [Cites] Cancer. 1989 Oct 15;64(8):1686-93 [2790683.001]
  • [Cites] J Natl Cancer Inst. 1990 May 16;82(10):855-8 [2185367.001]
  • [Cites] N Engl J Med. 1992 Apr 23;326(17):1115-22 [1532439.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):252-8 [1599017.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1308-16 [9694719.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S21-4 [9926233.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S31-8 [9926235.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • [Cites] N Engl J Med. 1999 Apr 22;340(16):1239-47 [10210707.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3964-72 [10339506.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1685-91 [10362793.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):90-6 [15389259.001]
  • [Cites] Am J Pathol. 2005 Jan;166(1):127-34 [15632006.001]
  • [Cites] J Pathol. 2005 Apr;205(5):541-7 [15732141.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Apr 15;158(2):167-71 [15796964.001]
  • [Cites] Br J Haematol. 2005 Apr;129(2):199-205 [15813847.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4048-56 [15961758.001]
  • [Cites] Lancet. 2005 Jun 25-Jul 1;365(9478):2216-24 [15978930.001]
  • [Cites] Histopathology. 2005 Jul;47(1):101-10 [15982329.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):26-33 [16007865.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5052-60 [15955904.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):747-55 [16084943.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5739-45 [16009944.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] Ann Hematol. 2005 Oct;84(10):661-6 [15875183.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1411-21 [16224207.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1581-91 [16236613.001]
  • [Cites] Mod Pathol. 2005 Dec;18(12):1542-9 [16056244.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:231-8 [16304386.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2360-2 [16224482.001]
  • [Cites] Cell Signal. 2006 Apr;18(4):449-55 [15967637.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):92-100 [16360421.001]
  • [Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):7 [16391364.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):495-501 [16396774.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 1):66-76 [16399588.001]
  • [Cites] J Pathol. 2006 Feb;208(3):423-30 [16353293.001]
  • [Cites] Expert Opin Ther Targets. 2006 Feb;10(1):27-35 [16441226.001]
  • [Cites] Adv Cancer Res. 2002;84:277-312 [11883530.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):567-72 [11920617.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2493-503 [11971184.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:11-8 [12078890.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:44-51 [12078902.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:75-8 [12078907.001]
  • [Cites] Oncogene. 2002 May 2;21(19):3095-102 [12082542.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):4908-20 [12118370.001]
  • [Cites] J Pathol. 2002 Nov;198(3):310-6 [12375263.001]
  • [Cites] Immunity. 2002 Oct;17(4):473-85 [12387741.001]
  • [Cites] Arthritis Rheum. 2002 Dec;46(12):3151-8 [12483718.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):16-26 [12502924.001]
  • [Cites] Blood. 2003 Jan 15;101(2):706-10 [12393409.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1505-12 [12393731.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1813-8 [12685837.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] Int J Hematol. 2003 May;77(4):330-5 [12774919.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2114-20 [12796376.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):843-58 [12852658.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):706-12 [12866030.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Oct;38(2):126-36 [12939740.001]
  • [Cites] Leuk Lymphoma. 2003 Aug;44(8):1325-31 [12952225.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Sep;11(3):206-13 [12966346.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1346-56 [14508396.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2214-9 [14523479.001]
  • [Cites] J Pathol. 2003 Nov;201(3):413-20 [14595753.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3434-40 [16868249.001]
  • [Cites] Pathobiology. 2006;73(3):107-25 [17085956.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1326-9 [17438085.001]
  • [Cites] J Clin Pathol. 2007 Oct;60(10):1092-7 [17158640.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1252-7 [18594468.001]
  • [Cites] Blood. 2005 May 15;105(10):4051-9 [15677564.001]
  • [Cites] Arch Pathol Lab Med. 1992 Sep;116(9):969-72 [1524465.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):859-67 [1384376.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):885-95 [1415907.001]
  • [Cites] Semin Diagn Pathol. 1992 Nov;9(4):297-303 [1480852.001]
  • [Cites] Am J Surg Pathol. 1993 Feb;17(2):123-32 [8422110.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):261-8 [1303125.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1595-602 [8123850.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):526-30 [8172327.001]
  • [Cites] Br J Haematol. 1994 Mar;86(3):513-23 [7519036.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):413-8 [7824015.001]
  • [Cites] Ann Oncol. 1995 May;6(5):477-82 [7545429.001]
  • [Cites] Am J Surg Pathol. 1995 Nov;19(11):1294-9 [7573692.001]
  • [Cites] Int J Cancer. 1996 Apr 10;66(2):179-83 [8603808.001]
  • [Cites] Blood. 1996 May 1;87(9):3844-51 [8611711.001]
  • [Cites] Leukemia. 1996 May;10(5):829-35 [8656679.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1279-87 [8827036.001]
  • [Cites] Nature. 1996 Oct 10;383(6600):538-42 [8849727.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1495-505 [8879220.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Semin Cancer Biol. 1996 Aug;7(4):217-26 [8946606.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):543-62 [9033270.001]
  • [Cites] Immunol Today. 1997 Apr;18(4):156-63 [9136451.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 2:79-81 [9209647.001]
  • [Cites] Pathology. 1997 Aug;29(3):294-9 [9271021.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):229-35 [9520936.001]
  • [Cites] Blood. 1998 Aug 1;92(3):790-4 [9680346.001]
  • [Cites] Leukemia. 1998 Aug;12(8):1272-6 [9697883.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2493-500 [16304050.001]
  • [Cites] Immunol Lett. 2006 Apr 15;104(1-2):83-8 [16386314.001]
  • [Cites] Indian Pediatr. 2006 Feb;43(2):141-7 [16528110.001]
  • [Cites] Trends Immunol. 2006 May;27(5):203-5 [16563865.001]
  • [Cites] Ann Hematol. 2006 Jul;85(7):463-8 [16534596.001]
  • [Cites] Am J Clin Pathol. 2006 May;125(5):776-82 [16707382.001]
  • [Cites] Yale J Biol Med. 2005 Jul;78(4):203-10 [16720015.001]
  • [Cites] Herpes. 2006 May;13(1):12-6 [16732997.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5716-22 [16740709.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):1010-8 [16648862.001]
  • [Cites] Int J Hematol. 2006 Jun;83(5):391-7 [16787868.001]
  • [Cites] Int J Hematol. 2006 Jun;83(5):398-403 [16787869.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):469-78 [16894295.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):352-60 [16770772.001]
  • [Cites] Acta Haematol. 2006;116(2):101-7 [16914904.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(13):2037-49 [16919769.001]
  • [Cites] Virchows Arch. 2006 Sep;449(3):315-9 [16896892.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1518-22 [16966262.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Sep;28(9):552-8 [17006259.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4626-33 [16954517.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1844-51 [16983704.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1863-71 [17064999.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1932-40 [17065008.001]
  • [Cites] Tumour Biol. 2006;27(6):329-33 [17033203.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2115-27 [17071485.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10332-8 [17079453.001]
  • (PMID = 19525189.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC011070-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 204
  • [Other-IDs] NLM/ NIHMS161993; NLM/ PMC2806063
  •  go-up   go-down


22. Pastor MA, Vasco B, Mosquera JM, Debén G, Bautista P, Requena L: [Two HHV8-related illnesses in a HIV-negative patient: Kaposi's sarcoma and multicentric Castleman's disease. Response to treatment with Rituximab and CHOP]. Actas Dermosifiliogr; 2006 Jul-Aug;97(6):385-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two HHV8-related illnesses in a HIV-negative patient: Kaposi's sarcoma and multicentric Castleman's disease. Response to treatment with Rituximab and CHOP].
  • [Transliterated title] Dos enfermedades relacionadas con el VHH-8 en un paciente VIH-negativo: sarcoma de Kaposi y enfermedad de Castleman multicéntrica. Respuesta a tratamiento con rituximab y CHOP.
  • Human herpes virus 8 (HHV8) was discovered in 1994 in the biopsy of a Kaposi's sarcoma in a patient with AIDS.
  • Since then it has been identified in all variants of Kaposi's sarcoma and in another two rare disorders: multicentric Castleman's disease and primary body-cavity based lymphomas.
  • The case discusses a 68 year old, HIV-negative male patient, presenting Kaposi's sarcoma for one year and being monitored by dermatology, who presented for weakness, anorexia and fever.
  • A biopsy on one of the swellings led to findings characteristic of multicentric plasma cell variant Castleman's disease.
  • Blood tests for HHV8 and HIV were carried out, resulting positive and negative respectively (IgG anti-HHV8 positive, title 1/640, indirect immunofluorescence).
  • This paper discusses the case of a HIV-, HHV8+ patient, diagnosed with classic Kaposi's sarcoma, who developed multicentric plasma cell variant Castleman's disease.
  • The coincidence of two or more HHV8-related illnesses in a HIV-negative patient has rarely been described in medical literature.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Giant Lymph Node Hyperplasia / complications. HIV Seronegativity. Herpesvirus 8, Human. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / drug therapy. Skin Neoplasms / complications. Skin Neoplasms / drug therapy


23. Vilchez RA, Lopez-Terrada D, Middleton JR, Finch CJ, Killen DE, Zanwar P, Jorgensen JL, Butel JS: Simian virus 40 tumor antigen expression and immunophenotypic profile of AIDS-related non-Hodgkin's lymphoma. Virology; 2005 Nov 10;342(1):38-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simian virus 40 tumor antigen expression and immunophenotypic profile of AIDS-related non-Hodgkin's lymphoma.
  • Simian virus 40 (SV40) is associated with some systemic non-Hodgkin's lymphomas (NHL) among HIV-positive patients, based on assays for viral DNA sequences.
  • To investigate the possible production of the viral transforming protein, we examined age-matched case-control specimens from patients with HIV/AIDS for the expression of SV40 large tumor antigen (T-ag).
  • Fifty-five systemic NHL and 25 nonmalignant lymphoid and malignant nonlymphoid tissue control cases from two HIV community programs in Texas and New Jersey were scored for IHC positivity without knowledge of the PCR results.
  • IHC showed expression of SV40 T-ag among B-cell lymphomas, whereas none of the control tissue samples were positive for T-ag (12/55, 22% vs. 0/25, 0%; P = 0.01).
  • SV40 T-ag expression was detected only in B-cell lymphoma specimens that contained SV40 DNA sequences.
  • Not all lymphoma cells in a positive specimen stained for T-ag, and the reaction was lower intensity than observed in SV40 hamster tumors.
  • A germinal center B-cell-like (GCB) profile was more frequently expressed by SV40-positive tumors than in Epstein-Barr virus (EBV)-related lymphomas (10/12, 83% vs. 6/13, 46%; P = 0.05), whereas a non-GCB phenotype was more frequent in EBV-positive than in SV40-positive lymphomas (7/13, 54% vs. 2/12, 17%; P = 0.05).
  • This study shows that SV40 gene expression occurs in a fraction of cells in some B-cell lymphomas among patients with HIV/AIDS.
  • [MeSH-major] Antigens, Polyomavirus Transforming / genetics. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adult. Base Sequence. Case-Control Studies. DNA, Viral / genetics. DNA, Viral / isolation & purification. Female. Gene Expression. Genes, Viral. HIV-1. Humans. Immunophenotyping. Male. Middle Aged. Molecular Sequence Data. Neoplasm Recurrence, Local / immunology. Neoplasm Recurrence, Local / virology. Simian virus 40 / genetics. Simian virus 40 / isolation & purification

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122775.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI36211; United States / NCI NIH HHS / CA / CA104818
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / DNA, Viral
  •  go-up   go-down


24. Licci S, D'Antonio A, Boscaino A, Morelli L, Piscioli F, Abbate I, Donnorso RP, Del Nonno F: Non-Hodgkin lymphomas concurrent with HHV8-associated Kaposi's sarcoma in the same lymph node in AIDS and non-AIDS patients. Acta Haematol; 2007;118(1):47-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphomas concurrent with HHV8-associated Kaposi's sarcoma in the same lymph node in AIDS and non-AIDS patients.
  • BACKGROUND: The association between lymphomas and Kaposi's sarcoma has been described since 1920.
  • METHODS: Two cases of concurrent non-Hodgkin lymphoma and Kaposi's sarcoma in the same lymph node are described: a diffuse large B cell lymphoma in an AIDS patient and a T cell-rich large B cell lymphoma in a HIV-negative patient, complete with the clinical, immunohistological and molecular features, the latter ones defined after isolation of the different neoplastic areas by laser capture microdissection.
  • CONCLUSION: This study represents a further confirmation of the supposed different etiopathogenic mechanisms of the 2 neoplasias, suggesting a coincidental occurrence even when localized in the same lymph node, independently from HIV infection.
  • [MeSH-major] Herpesvirus 8, Human / isolation & purification. Lymph Nodes / pathology. Lymphoma, AIDS-Related / pathology. Lymphoma, Non-Hodgkin / pathology. Sarcoma, Kaposi / pathology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17505129.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


25. Epeldegui M, Vendrame E, Martínez-Maza O: HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma. Immunol Res; 2010 Dec;48(1-3):72-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma.
  • HIV infection is associated with a much higher risk for the development of non-Hodgkin lymphoma (AIDS-NHL).
  • The principal causes of lymphomagenesis in HIV-infected individuals are thought to be the loss of immune function seen in HIV infection, which results in the loss of immunoregulation of Epstein-Barr virus-infected B cells, as well as HIV infection-associated immune dysregulation, including chronic B-cell activation.
  • In this review, we discuss recent reports that further support the importance of these factors, and we highlight emerging evidence of different mechanisms that potentially drive lymphomagenesis in HIV-infected individuals.
  • [MeSH-major] AIDS-Related Opportunistic Infections / immunology. Acquired Immunodeficiency Syndrome / immunology. B-Lymphocytes / immunology. Epstein-Barr Virus Infections / immunology. HIV / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / immunology


26. Kelemen K, Cao W, Peterson LC, Evens AM, Variakojis D: Primary mediastinal large B-cell lymphoma in HIV: report of two cases. J Hematop; 2009 Mar;2(1):45-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large B-cell lymphoma in HIV: report of two cases.
  • Primary mediastinal large B cell lymphoma (PMLBCL) is a subtype of diffuse large B cell lymphoma arising in the mediastinum with distinctive clinical and morphological features.
  • Though diffuse large B cell lymphoma is one of the most common non-Hodgkin lymphoma associated with AIDS, there are no data available regarding the association of HIV and PMLBCL.
  • We report here two cases of PMLBCL arising in AIDS patients.
  • One of the two patients, a 25-year-old woman who had localized disease and evidence of Epstein-Barr virus in lymphoma cells, did not respond to chemotherapy and died of disease progression 5 months after diagnosis.
  • The second patient, a 38-year-old male with disseminated disease, responded to therapy and is disease-free after 9 months of follow-up.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Pathol Jpn. 1993 Jan-Feb;43(1-2):44-54 [8465656.001]
  • [Cites] J Pathol. 1992 Aug;167(4):381-4 [1328576.001]
  • [Cites] Blood. 1991 Aug 1;78(3):780-8 [1713514.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • [Cites] Blood. 2007 Aug 1;110(3):972-8 [17400912.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Am J Med Sci. 2005 Mar;329(3):136-8 [15767818.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):1135-48 [8880201.001]
  • [Cites] Br J Haematol. 1995 Jun;90(2):235-43 [7794745.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]
  • (PMID = 19669223.001).
  • [ISSN] 1868-9256
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2713493
  •  go-up   go-down


27. Wilkins K, Turner R, Dolev JC, LeBoit PE, Berger TG, Maurer TA: Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol; 2006 Feb;54(2):189-206; quiz 207-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous malignancy and human immunodeficiency virus disease.
  • Certain skin cancers occur with increased frequency or altered course in patients infected with HIV.
  • Malignant melanoma and squamous cell carcinoma are examples of cutaneous malignancies that have a more aggressive course in patients with HIV.
  • The incidence of HIV-associated Kapsosi's sarcoma has markedly decreased since the advent of HIV antiretroviral therapy.
  • Cutaneous T-cell lymphoma (CTCL) is rare in this population.
  • Other types of cutaneous lymphoma and HIV-associated pseudo-CTCL are discussed.
  • LEARNING OBJECTIVE: At the completion of this learning activity, participants should be familiar with the unique epidemiology, clinical course, and management of cutaneous malignancy in patients infected with HIV.
  • [MeSH-major] HIV Infections / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Algorithms. Animals. Anti-Retroviral Agents / administration & dosage. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Herpesviridae Infections / epidemiology. Herpesvirus 8, Human / isolation & purification. Humans. Immunity, Cellular. Immunohistochemistry. Lymphoma, Large-Cell, Anaplastic / epidemiology. Lymphoma, T-Cell, Cutaneous / epidemiology. Lymphoma, T-Cell, Cutaneous / immunology. Lymphoma, T-Cell, Cutaneous / pathology. Melanoma / epidemiology. Melanoma / therapy. Papillomaviridae. Papillomavirus Infections / epidemiology. Risk Factors. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Seroepidemiologic Studies

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443048.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 274
  •  go-up   go-down


28. Navarro JT, Ribera JM, Oriol A, Xicoy B, Mate JL, Sirera G, Lloveras N, Millá F, Feliu E: Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy. Int J Hematol; 2007 Nov;86(4):337-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy.
  • In the era of highly active antiretroviral therapy (HAART), the prognosis for acquired immunodeficiency syndrome-related lymphomas (ARL) seems to be similar to that for aggressive B-cell lymphomas in human immunodeficiency virus (HIV)-negative patients.
  • We evaluated the prognostic factors for response and survival in a series of HIV-infected patients with systemic non-Hodgkin's lymphoma (NHL) in the HAART era.
  • The 5-year disease-free survival (DFS) probability (95% confidence interval [CI]) was 73% (54%-92%).
  • A disease stage of III to IV was the only parameter with prognostic influence on DFS.
  • The factors influencing OS were an International Prognostic Index >2, an Eastern Cooperative Ecology Group (ECOG) score >2, and a disease stage of III to IV.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / pathology. Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Cyclophosphamide. Disease-Free Survival. Doxorubicin. Female. HIV / physiology. Humans. Male. Prednisolone. Prognosis. Vincristine


29. Benicchi T, Ghidini C, Re A, Cattaneo C, Casari S, Caimi L, Rossi G, Imberti L: T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma. Transplantation; 2005 Sep 15;80(5):673-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma.
  • BACKGROUND: One of the major concern for high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT) for HIV-associated lymphoma is that posttransplant immunosuppression might worsen immune defects of HIV individuals.
  • Since the introduction of highly active antiretroviral therapy has made HSCT possible also in these patients, we analyzed whether the immune system already compromised by HIV infection might support an efficient T-cell recovery after HSCT.
  • METHODS: The kinetics and the extent of T-cell reconstitution were investigated before and after HSCT in four patients with HIV-related lymphoma (one with Hodgkin's Disease and three with non-Hodgkin's lymphoma) by measuring the thymic output, the level of IL-7 and the heterogeneity of T-cell repertoire.
  • CONCLUSIONS: High-dose therapy and HSCT in HIV patients under highly active antiretroviral therapy does not worsen the immune defects.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / therapy


30. Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M, PETHEMA, GELTAMO, GELCAB and GESIDA Groups: Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol; 2008 Feb;140(4):411-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
  • Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) is the standard treatment in non-immunosuppressed patients with diffuse large B-cell lymphoma (DLBCL), but its adequacy has not been definitively established in patients with human immunodeficiency virus (HIV)-related lymphoma.
  • This phase II trial aimed to evaluate the safety and efficacy of six cycles of R-CHOP in patients with HIV-related DLBCL and to determine whether response to highly active antiretroviral therapy (HAART) had prognostic impact.
  • Complete response was achieved in 55 (69%) patients, with an estimated 3-year disease-free survival of 77% and 3-year overall survival of 56%.
  • In HIV-related DLBCL R-CHOP is feasible, safe and effective.
  • The prognosis depends on lymphoma-related parameters and on the response to HAART.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162120.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


31. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, Mi S, Yam P, Stinson S, Kalos M, Alvarnas J, Lacey SF, Yee JK, Li M, Couture L, Hsu D, Forman SJ, Rossi JJ, Zaia JA: RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med; 2010 Jun 16;2(36):36ra43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.
  • AIDS patients who develop lymphoma are often treated with transplanted hematopoietic progenitor cells.
  • As a first step in developing a hematopoietic cell-based gene therapy treatment, four patients undergoing treatment with these transplanted cells were also given gene-modified peripheral blood-derived (CD34(+)) hematopoietic progenitor cells expressing three RNA-based anti-HIV moieties (tat/rev short hairpin RNA, TAR decoy, and CCR5 ribozyme).
  • In vitro estimates of successful expression of the anti-HIV moieties were initially as high as 22% but declined to approximately 1% over 4 weeks of culture.
  • Transfected cells were successfully engrafted in all four infused patients by day 11, and there were no unexpected infusion-related toxicities.
  • These results support the development of an RNA-based cell therapy platform for HIV.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2007 Dec;25(12):1444-54 [18066041.001]
  • [Cites] Mol Ther. 2007 Jun;15(6):1182-8 [17406343.001]
  • [Cites] Hum Gene Ther. 2008 Jun;19(6):622-34 [18533892.001]
  • [Cites] J Gene Med. 2008 Oct;10(10):1059-70 [18642399.001]
  • [Cites] Gene Ther. 2008 Dec;15(23):1536-49 [18800151.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] Nat Med. 2009 Mar;15(3):285-92 [19219022.001]
  • [Cites] Science. 2009 Mar 6;323(5919):1304-7 [19265012.001]
  • [Cites] Mol Ther. 2009 May;17(5):844-50 [19259065.001]
  • [Cites] Science. 2009 Nov 6;326(5954):818-23 [19892975.001]
  • [Cites] Gene Ther. 2010 Mar;17(3):389-99 [19865182.001]
  • [Cites] Blood. 2002 Jan 15;99(2):698-701 [11781257.001]
  • [Cites] Mol Ther. 2002 Apr;5(4):479-84 [11945076.001]
  • [Cites] Gene Ther. 2002 Aug;9(16):1055-64 [12140733.001]
  • [Cites] Gene Ther. 2002 Dec;9(24):1730-4 [12457288.001]
  • [Cites] Mol Ther. 2003 Mar;7(3):325-33 [12668128.001]
  • [Cites] Mol Ther. 2003 Jul;8(1):62-71 [12842429.001]
  • [Cites] Mol Ther. 2003 Aug;8(2):196-206 [12907142.001]
  • [Cites] Blood. 2004 Feb 1;103(3):796-803 [12920024.001]
  • [Cites] Hum Gene Ther. 2004 Mar;15(3):251-62 [15018734.001]
  • [Cites] J Gene Med. 2004 Mar;6(3):268-77 [15026988.001]
  • [Cites] Nature. 1988 Sep 29;335(6189):395-6 [3166513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9870-4 [1409715.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 1994 Jul 15;84(2):421-32 [7517715.001]
  • [Cites] Science. 1996 Apr 12;272(5259):263-7 [8602510.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4618-28 [8639830.001]
  • [Cites] Gene Ther. 1996 Aug;3(8):717-24 [8854097.001]
  • [Cites] J Virol. 1997 Jun;71(6):4707-16 [9151864.001]
  • [Cites] J Virol. 1999 May;73(5):3649-60 [10196257.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] Clin Immunol. 2005 Apr;115(1):26-32 [15870017.001]
  • [Cites] Mol Ther. 2005 Jul;12(1):77-86 [15963923.001]
  • [Cites] Mol Ther. 2005 Oct;12(4):697-706 [16039909.001]
  • [Cites] Mol Ther. 2005 Nov;12(5):900-9 [16115802.001]
  • [Cites] Mol Ther. 2006 Feb;13(2):366-73 [16325473.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1751-60 [16269617.001]
  • [Cites] Clin Infect Dis. 2006 Apr 1;42(7):1003-10 [16511767.001]
  • [Cites] Mol Ther. 2006 Oct;14(4):494-504 [16844419.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3305-12 [16857988.001]
  • [Cites] Mol Ther. 2007 May;15(5):1024-33 [17356541.001]
  • [Cites] Methods Mol Biol. 2008;434:99-112 [18470641.001]
  • (PMID = 20555022.001).
  • [ISSN] 1946-6242
  • [Journal-full-title] Science translational medicine
  • [ISO-abbreviation] Sci Transl Med
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000043-49; United States / NIAID NIH HHS / AI / AI61839; United States / NHLBI NIH HHS / HL / R01 HL074704; United States / NIAID NIH HHS / AI / AI42552; United States / NCI NIH HHS / CA / CA107399-05; United States / NIAID NIH HHS / AI / P01 AI061839-04; United States / NIAID NIH HHS / AI / R37 AI029329; United States / NCRR NIH HHS / RR / RR000043-49; United States / NIAID NIH HHS / AI / AI061839-04; United States / NHLBI NIH HHS / HL / HL07470; United States / NCI NIH HHS / CA / P50 CA107399-05; United States / NCRR NIH HHS / RR / M01 RR00043; United States / NCRR NIH HHS / RR / RR025083-01; United States / NCI NIH HHS / CA / P30 CA33572-26; United States / NCRR NIH HHS / RR / S10 RR025083-01; United States / NIAID NIH HHS / AI / AI042552-11; United States / NCI NIH HHS / CA / P30 CA033572-29; United States / NCRR NIH HHS / RR / M01 RR000043; United States / NHLBI NIH HHS / HL / R01 HL074704-07; United States / NIAID NIH HHS / AI / P01 AI061839; United States / NCI NIH HHS / CA / P30 CA033572; United States / NIAID NIH HHS / AI / R01 AI042552; United States / NCRR NIH HHS / RR / S10 RR025083; United States / NIAID NIH HHS / AI / R01 AI042552-11; United States / NCRR NIH HHS / RR / S10RR025083-01; United States / NHLBI NIH HHS / HL / HL074704-07; United States / NCI NIH HHS / CA / P50 CA107399
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 63231-63-0 / RNA
  • [Other-IDs] NLM/ NIHMS305014; NLM/ PMC3130552
  •  go-up   go-down


32. Galicier L, Fieschi C, Borie R, Meignin V, Daniel MT, Gérard L, Oksenhendler E: Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood; 2007 Oct 15;110(8):2846-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.
  • Prognosis of acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin lymphoma has improved since the introduction of highly active antiretroviral therapy.
  • Burkitt lymphomas (BLs) still have poor outcome in patients with bone marrow (BM) or central nervous system (CNS) involvement when treated with standard-dose chemotherapy.
  • We have prospectively evaluated the LMB86 regimen in 63 human immunodeficiency virus (HIV)-infected patients with stage IV (BM and/or CNS involvement) BL consecutively recruited between November 1992 and January 2006.
  • Seven treatment-related deaths occurred and all patients experienced severe BM toxicity.
  • The estimate 2-year overall survival and disease-free survival were 47.1% (95% CI, 34-59.1) and 67.8% (95% CI, 51-80), respectively.
  • We conclude that LMB86 regimen is highly effective in advanced HIV-related BL and should be proposed for patients with CD4 count higher than 200 x 10(6)/L or ECOG of 2 or less.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Kaplan-Meier Estimate. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Prospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609431.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


33. Rajaram ST, Lobo FD, Achary C: Oropharyngeal plasmablastic lymphoma in a man with human immunodeficiency virus infection: A case report. Ear Nose Throat J; 2010 Dec;89(12):E13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oropharyngeal plasmablastic lymphoma in a man with human immunodeficiency virus infection: A case report.
  • Oropharyngeal lymphomas are rare, typically high-grade neoplasms.
  • We describe a case of plasmablastic lymphoma that originated in the oropharynx of a 40-year-old man who was positive for human immunodeficiency virus (HIV).
  • In HIV-positive patients, non-Hodgkin lymphomas frequently involve sites, including the oropharynx, that are unusual in patients without HIV.
  • [MeSH-major] HIV Infections / diagnosis. Lymphoma, AIDS-Related / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Oropharyngeal Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Deglutition Disorders / diagnosis. Deglutition Disorders / etiology. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. Male. Neoplasm Staging. Risk Assessment. Treatment Refusal

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21174265.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Zucchetto A, Bruzzone S, De Paoli A, Regine V, Pappagallo M, Dal Maso L, Serraino D, Rezza G, Suligoi B: [AIDS and injecting drug use: survival determinants in the highly active antiretroviral therapy era]. Epidemiol Prev; 2009 Jul-Oct;33(4-5):184-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS and injecting drug use: survival determinants in the highly active antiretroviral therapy era].
  • [Transliterated title] AIDS e tossicodipendenza: determinanti della sopravvivenza nell'era delle terapie antiretrovirali altamente efficaci.
  • OBJECTIVES: to estimate survival, after AIDS diagnosis, in people who got infected with HIV through injecting drug use (IDUs), to identify among variables collected at AIDS diagnosis those which were associated to prognosis and to assess the frequency of morbid conditions at death.
  • SETTING AND PARTICIPANTS: 4,040 IDUs diagnosed with AIDS in Italy between 1999 and 2005.
  • RESULTS: the 2-year and 5-year survival probabilities after AIDS diagnosis of IDUs were 72% and 60%, respectively.
  • Elevated risks of death emerged for IDUs with older ages (HR=2.0 95% CI 1.6-2.4 for>45 years old vs.<35 years old), lower education (HR=1.4 95% CI 1.2-1.7 for elementary school vs. high school/university), longer time span between first HIV positive test and AIDS diagnosis (HR=1.6 95% CI 1.4-1.9 for > 6 months vs. < 6 months), and lower CD4 cell count at diagnosis (HR=1.5 95% CI 1.3-1.7 for <50 cells/mm3 vs. > 200 cells/mm3).
  • Compared to Pneumocystis carinii pneumonia, non-Hodgkin lymphomas were the worst prognostic factors, particularly primary brain lymphoma (HR=7.2, 95% CI 4.4-11.8).
  • 52% of cases reported no AIDS-defining illnesses: 64 (4%) violent causes, 94 (6%) cancers, and 656 (42%) only non neoplastic illnesses, among which 415 (27%) liver diseases.
  • CONCLUSION: the results of this population-based study showed that, in the highly active antiretroviral therapy era, survival of IDUs with AIDS was still lower compared to that of HIV sexual transmission groups.
  • The presence at death, in 52% of cases, of non AIDS-defining illnesses indicates the important role on mortality of co-morbidities, including liver diseases and violent causes.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / mortality. Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Substance Abuse, Intravenous / epidemiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / mortality. Age Factors. Comorbidity. Death Certificates. Educational Status. Equipment Contamination. HIV Infections / transmission. Homicide / statistics & numerical data. Humans. Italy / epidemiology. Kaplan-Meier Estimate. Liver Diseases / mortality. Lymphoma, AIDS-Related / mortality. Medical Record Linkage. Needles. Proportional Hazards Models. Registries. Retrospective Studies. Risk. Sexual Behavior


35. Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, Young AM, Powles T, Gaya A, Nelson M, Stebbing J: A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med; 2005 Aug 16;143(4):265-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy.
  • BACKGROUND: The established International Prognostic Index for lymphomas has not included patients with systemic AIDS-related non-Hodgkin lymphoma.
  • OBJECTIVE: To establish the most appropriate prognostic index for use in patients with systemic AIDS-related non-Hodgkin lymphoma.
  • DESIGN: A prospective study involving univariate and multivariable analyses of patients with AIDS-related non-Hodgkin lymphoma whose data were used to examine standard and new criteria for survival after diagnosis.
  • SETTING: The Chelsea and Westminster cohort of HIV-1-infected persons.
  • PATIENTS: 9621 HIV-positive patients, 111 in whom AIDS-related non-Hodgkin lymphoma was treated after 1996, in the era of highly active antiretroviral therapy (HAART).
  • RESULTS: Survival of patients with AIDS-related non-Hodgkin lymphoma has increased in the HAART era (log-rank chi-square, 9.23; P = 0.002).
  • Regression modeling for patients in whom disease was diagnosed after 1996 revealed only 2 independent predictors of death: International Prognostic Index risk group and CD4 cell count.
  • CONCLUSIONS: For patients with AIDS-related non-Hodgkin lymphoma that was diagnosed in the era of HAART, application of the International Prognostic Index remains useful.
  • Patients who present with AIDS-related non-Hodgkin lymphoma and a low CD4 cell count have a poor prognosis; this information can be used to guide therapeutic options.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality


36. Singh J, Malani AK, Ganguly S, Kambhampati S: HAART- and AIDS-related lymphomas. Blood; 2006 Nov 15;108(10):3621; author reply 3621-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HAART- and AIDS-related lymphomas.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • (PMID = 17085718.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


37. Serraino D, Zucchetto A, Suligoi B, Bruzzone S, Camoni L, Boros S, De Paoli A, Dal Maso L, Franceschi S, Rezza G: Survival after AIDS diagnosis in Italy, 1999-2006: a population-based study. J Acquir Immune Defic Syndr; 2009 Sep 1;52(1):99-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after AIDS diagnosis in Italy, 1999-2006: a population-based study.
  • OBJECTIVES: To provide survival estimates of Italian people with AIDS (PWA) in the highly active antiretroviral therapy era and to identify prognostic factors at diagnosis and illnesses present at death.
  • Non-Hodgkin lymphoma at AIDS diagnosis was the strongest negative prognostic factor, particularly in the first 12 months after AIDS (hazard ratio = 9.2, for primary brain lymphoma).
  • At death, non-AIDS-defining illnesses increased from 38.4% in 1999 to 56.9% in 2006, with non-AIDS-defining cancers rising from 3.7% to 8.7%.
  • CONCLUSIONS: Our study documented the prolonged survival of Italian PWA, the strong impact of non-Hodgkin lymphoma on mortality, and the increasing frequency of non-AIDS-defining illnesses at death.
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / mortality. Female. Humans. Italy / epidemiology. Longitudinal Studies. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / mortality. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448558.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. D'Souza GA, Sunad R, Rajagopalan N, Ananthamurthy A, Murthy KR, Babu K: NK/T-cell lymphoma in AIDS. J Assoc Physicians India; 2006 Nov;54:890-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NK/T-cell lymphoma in AIDS.
  • A 42-year-old man diagnosed to be HIV positive and on highly active antiretroviral treatment (HAART), presented with double vision and gradual drooping of the left eyelid.
  • Further workup showed the mass to be an NK/T cell lymphoma.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, T-Cell / diagnosis. Nose Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249261.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


39. Kang KM, Song DS, Park JM, Jung CK, Hong YS, Kang MW, Park CW: Four cases of non-Hodgkin's lymphoma in AIDS patients. Korean J Intern Med; 2006 Dec;21(4):266-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four cases of non-Hodgkin's lymphoma in AIDS patients.
  • The incidence of opportunistic infection has decreased since the introduction of highly active antiretroviral therapy, so lymphoma is now far and away the most lethal complication of acquired immunodeficiency syndrome.
  • We have experienced four cases of NHL in AIDS patients.
  • The first patient was a 37 year old male who presented with left sided hemiplegia due to CNS lymphoma.
  • The second patient was a 40 year old male who was admitted because of jaundice; he was diagnosed as having lymphoma that exclusively involved the liver.
  • The third patient was a 38-year-old male who presented with palpable mass in the left cervical region, which was diagnosed as lymphoma.
  • Above three cases were confirmed as diffuse large B cell lymphoma.
  • The latter case is the first report of NHL involving the chest wall musculature in a Korean AIDS patient.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, Non-Hodgkin / complications

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):863-73 [11298581.001]
  • [Cites] Korean J Intern Med. 2001 Mar;16(1):1-7 [11417298.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):430-5 [11433410.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):349-51 [12688356.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1981 Jun 5;30(21):250-2 [6265753.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] JAMA. 1989 Feb 3;261(5):719-24 [2536124.001]
  • [Cites] Ann Intern Med. 1990 Aug 15;113(4):276-82 [1973886.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):515-24 [9711914.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • (PMID = 17249512.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3891035
  •  go-up   go-down


40. Corti M, Villafañe Fioti MF, Lewi D, Schtirbu R, Narbaitz M, de Dios Soler M: [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients]. Acta Gastroenterol Latinoam; 2006 Dec;36(4):190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients].
  • [Transliterated title] Linfomas del tubo digestivo y glándulas anexas en pacientes con SIDA. Serie de casos.
  • BACKGROUND: Non-Hodgkin's lymphoma (NHL) is the second most common neoplasm among patients with AIDS.
  • One of the major clinical characteristics of AIDS-associated NHL is the high frequency of extra-nodal involvement, including the gastrointestinal tract, at initial presentation.
  • METHODS: From January 1997 to December 2004, 8 cases of NHL of the digestive tract and anexal glands (liver and parotid gland) were observed at the HIV/AIDS division of the Infectious Diseases FJ Muñiz Hospital from Buenos Aires, Argentina.
  • No patient was receiving highly active antiretroviral therapy (HAART) at lymphoma diagnosis.
  • The global incidence of AIDS-associated lymphomas (central nervous system lymphomas, non-Hodgkin lymphomas and Hodgkin lymphoma) during the time of study was 2,9% (54 cases); 17 patients (32%) had diagnosis of systemic NHL; 10 (58,8%) of them were extranodal at the onset of clinical symptoms and 8 (80%) involvement the digestive tract and anexal glands (parotid gland, cavum, esophagus, stomach, duodenum, the right colon in 2 patients and the liver), as primary NHL of high grade and "B" phenotype.
  • Primary duodenal lymphoma was the only Burkitt lymphoma of this serie and we detected the Epstein-Barr virus genome in the biopsy smears of this tumor and in the hepatic lymphoma.
  • CONCLUSION: NHL of the gastrointestinal tract is a severe complication of advanced HIV/AIDS disease.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Parotid Neoplasms / diagnosis


41. Navarro CM, Shibli JA, Ferrari RB, d'Avila S, Sposto MR: Gingival primary extranodal non-Hodgkin's lymphoma as the first manifestation of acquired immunodeficiency syndrome. J Periodontol; 2008 Mar;79(3):562-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival primary extranodal non-Hodgkin's lymphoma as the first manifestation of acquired immunodeficiency syndrome.
  • BACKGROUND: Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative malignancies that may be associated with acquired immunodeficiency syndrome (AIDS).
  • This report presents and discusses two unusual cases of gingival primary extranodal non-Hodgkin's lymphoma (PE-NHL) as the first manifestation of AIDS.
  • The patients were tested for human immunodeficiency virus (HIV) infection.
  • RESULTS: The clinicopathological evaluation and the serological HIV examination of the patients led us to the final diagnosis of gingival PE-NHL as the first manifestation of AIDS.
  • Both patients were referred to an oncologist and to an infectious disease specialist and were given antineoplastic chemotherapy and highly active antiretroviral therapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Gingival Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18315441.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


42. Trobridge GD, Wu RA, Beard BC, Chiu SY, Muñoz NM, von Laer D, Rossi JJ, Kiem HP: Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One; 2009 Nov 02;4(11):e7693
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection.
  • BACKGROUND: There is currently no effective AIDS vaccine, emphasizing the importance of developing alternative therapies.
  • Recently, a patient was successfully transplanted with allogeneic, naturally resistant CCR5-negative (CCR5Delta32) cells, setting the stage for transplantation of naturally resistant, or genetically modified stem cells as a viable therapy for AIDS.
  • Hematopoietic stem cell (HSC) gene therapy using vectors that express various anti-HIV transgenes has also been attempted in clinical trials, but inefficient gene transfer in these studies has severely limited the potential of this approach.
  • Here we evaluated HSC gene transfer of an anti-HIV vector in the pigtailed macaque (Macaca nemestrina) model, which closely models human transplantation.
  • METHODS AND FINDINGS: We used lentiviral vectors that inhibited both HIV-1 and simian immunodeficiency virus (SIV)/HIV-1 (SHIV) chimera virus infection, and also expressed a P140K mutant methylguanine methyltransferase (MGMT) transgene to select gene-modified cells by adding chemotherapy drugs.
  • The high marking levels allowed us to demonstrate protection from SHIV in lymphocytes derived from gene-modified macaque long-term repopulating cells that expressed an HIV-1 fusion inhibitor.
  • We observed a statistically significant 4-fold increase of gene-modified cells after challenge of lymphocytes from one macaque that received stem cells transduced with an anti-HIV vector (p<0.02, Student's t-test), but not in lymphocytes from a macaque that received a control vector.
  • We also established a competitive repopulation assay in a second macaque for preclinical testing of promising anti-HIV vectors.
  • The vectors we used were HIV-based and thus efficiently transduce human cells, and the transgenes we used target HIV-1 genes that are also in SHIV, so our findings can be rapidly translated to the clinic.
  • CONCLUSIONS: Here we demonstrate the ability to select protected HSC-derived lymphocytes in vivo in a clinically relevant nonhuman primate model of HIV/SHIV infection.
  • This approach can now be evaluated in human clinical trials in AIDS lymphoma patients.
  • In this patient setting, chemotherapy would not only kill malignant cells, but would also increase the number of MGMTP140K-expressing HIV-resistant cells.
  • This approach should allow for high levels of HIV-protected cells in AIDS patients to evaluate AIDS gene therapy.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2002 Jul 10;288(2):222-35 [12095387.001]
  • [Cites] Gene Ther. 2010 Jan;17(1):37-49 [19741733.001]
  • [Cites] J Med Primatol. 2002 Aug;31(4-5):237-56 [12390546.001]
  • [Cites] Science. 2003 Jun 13;300(5626):1749-51 [12805549.001]
  • [Cites] Science. 2003 Jun 27;300(5628):2036-9 [12829768.001]
  • [Cites] Nat Rev Drug Discov. 2003 Aug;2(8):624-34 [12904812.001]
  • [Cites] Mol Ther. 2003 Aug;8(2):196-206 [12907142.001]
  • [Cites] J Clin Invest. 2003 Nov;112(10):1581-8 [14617759.001]
  • [Cites] J Virol. 2004 Jan;78(2):568-75 [14694088.001]
  • [Cites] Hum Gene Ther. 2004 Mar;15(3):251-62 [15018734.001]
  • [Cites] Curr Gene Ther. 2004 Mar;4(1):15-31 [15032611.001]
  • [Cites] Blood. 2004 May 15;103(10):3710-6 [14739227.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4062-9 [14976042.001]
  • [Cites] J Immunol. 1985 Feb;134(2):971-6 [3871222.001]
  • [Cites] Immunogenetics. 1985;21(3):235-46 [3872841.001]
  • [Cites] Hum Gene Ther. 1999 Nov 20;10(17):2769-78 [10584923.001]
  • [Cites] Microbes Infect. 2000 Feb;2(2):223-9 [10742694.001]
  • [Cites] AIDS. 1999;13 Suppl A:S113-20 [10885770.001]
  • [Cites] Hum Gene Ther. 2000 Sep 20;11(14):2025-37 [11020801.001]
  • [Cites] Ann N Y Acad Sci. 2000 Nov;918:318-29 [11131719.001]
  • [Cites] J Pharmacol Exp Ther. 2001 May;297(2):524-30 [11303039.001]
  • [Cites] Hum Gene Ther. 2001 Jun 10;12(9):1013-9 [11399224.001]
  • [Cites] Mol Ther. 2002 Jan;5(1):33-41 [11786043.001]
  • [Cites] J Virol. 1992 Apr;66(4):2232-9 [1548759.001]
  • [Cites] J Virol. 1992 Dec;66(12):7517-21 [1433527.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6221-7 [7954470.001]
  • [Cites] J Med Primatol. 1996 Jun;25(3):163-74 [8892037.001]
  • [Cites] J Virol. 1997 May;71(5):3932-9 [9094670.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1936-45 [9581836.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Curr Opin Biotechnol. 1998 Oct;9(5):457-63 [9821272.001]
  • [Cites] Science. 1999 Jan 29;283(5402):682-6 [9924027.001]
  • [Cites] Blood. 2005 Feb 1;105(3):997-1002 [15494421.001]
  • [Cites] Methods Mol Biol. 2005;309:261-72 [15990406.001]
  • [Cites] Hum Gene Ther. 2005 Dec;16(12):1355-66 [16390267.001]
  • [Cites] Nature. 2006 May 25;441(7092):537-41 [16724069.001]
  • [Cites] Nat Biotechnol. 2006 Jun;24(6):687-96 [16732270.001]
  • [Cites] Hum Gene Ther. 2006 Jun;17(6):577-88 [16776567.001]
  • [Cites] Mol Ther. 2006 Oct;14(4):494-504 [16844419.001]
  • [Cites] Retrovirology. 2006;3:76 [17078891.001]
  • [Cites] Mol Ther. 2007 Jan;15(1):76-85 [17164778.001]
  • [Cites] Blood. 2007 Jan 1;109(1):65-70 [16968897.001]
  • [Cites] J Virol. 2007 Mar;81(6):2700-12 [17182671.001]
  • [Cites] PLoS Pathog. 2007 Apr;3(4):e54 [17432934.001]
  • [Cites] Hum Gene Ther. 2007 May;18(5):451-6 [17536975.001]
  • [Cites] Exp Hematol. 2007 Jul;35(7):1132-9 [17588482.001]
  • [Cites] J Virol. 2007 Nov;81(22):12210-7 [17804491.001]
  • [Cites] Nat Med. 2007 Dec;13(12):1389-90 [18064013.001]
  • [Cites] Nat Biotechnol. 2007 Dec;25(12):1444-54 [18066041.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5537-43 [18388180.001]
  • [Cites] Gene Ther. 2008 Dec;15(23):1536-49 [18800151.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] Nat Med. 2009 Mar;15(3):285-92 [19219022.001]
  • [Cites] Hum Gene Ther. 2009 Apr;20(4):325-36 [19267665.001]
  • [Cites] Cell. 2002 Aug 23;110(4):521-9 [12202041.001]
  • (PMID = 19888329.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK047754; United States / NIAID NIH HHS / AI / R21 AI063959; United States / NIAID NIH HHS / AI / AI063959; United States / NIAID NIH HHS / AI / AI061839; United States / NHLBI NIH HHS / HL / P01 HL053750; United States / NIDDK NIH HHS / DK / DK056465; United States / NIDDK NIH HHS / DK / DK047754; United States / NIDDK NIH HHS / DK / P30 DK056465; United States / NIAID NIH HHS / AI / R01 AI080326; United States / NIAID NIH HHS / AI / P01 AI061839; United States / NHLBI NIH HHS / HL / HL053750
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AIDS Vaccines
  • [Other-IDs] NLM/ PMC2765621
  •  go-up   go-down


43. Gotoh M, Kitahara T, Iguchi T, Izumi M, Mukai K, Ohyashiki K: [HIV-related multiple non-Hodgkin lymphomas]. Rinsho Ketsueki; 2008 Nov;49(11):1552-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HIV-related multiple non-Hodgkin lymphomas].
  • He was HIV-positive, and had gastric diffuse large B-cell lymphoma and renal T-cell anaplastic large cell lymphoma (T-ALCL).
  • We diagnosed double lymphomas related to AIDS.
  • The patient received anti-retroviral therapy, and started the CHOP regimen for the double lymphomas, resulting in transient improvement.
  • Biopsy specimen demonstrated null cell ALCL, and this patient demonstrated multiple lymphomas.
  • This case suggested that cancer generation was promoted by low immunity, although it is known that ambivalent tumors such as non-Hodgkin lymphomas can occur frequently.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, T-Cell / diagnosis. Neoplasms, Multiple Primary. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047787.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


44. Madan RA, Chang VT, Dever LL: An uncommon presentation of HIV-related lymphoma. AIDS Patient Care STDS; 2007 Jul;21(7):443-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An uncommon presentation of HIV-related lymphoma.
  • Although highly active antiretroviral therapy has improved the clinical course of patients with HIV, this population remains at a significantly increased risk for non-Hodgkin's lymphoma (NHL).
  • We encountered a patient with HIV-related NHL who presented with a thoracic spinal cord compression and had a complicated clinical course as a result of the atypical presentation.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / complications. Lymphoma, Non-Hodgkin / virology. Spinal Cord Compression / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651024.001).
  • [ISSN] 1087-2914
  • [Journal-full-title] AIDS patient care and STDs
  • [ISO-abbreviation] AIDS Patient Care STDS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Levine AM: Management of AIDS-related lymphoma. Curr Opin Oncol; 2008 Sep;20(5):522-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of AIDS-related lymphoma.
  • PURPOSE OF REVIEW: With the advent of highly active antiretroviral therapy, the epidemiology of AIDS-lymphoma has changed, and prognosis has improved.
  • Although the incidence of AIDS-lymphoma has decreased, the incidence of HIV-associated Hodgkin's lymphoma has increased; mechanisms for these changes in epidemiology will be discussed.
  • RECENT FINDINGS: Use of highly active antiretroviral therapy, either concomitantly or immediately after completion of chemotherapy, has resulted in rates of complete remission and survival that are similar to those in HIV-negative patients.
  • The use of rituximab, while initially controversial because of reports of increased risk of infectious death, is associated with improved outcome; the increased risk of infectious death has not been confirmed.
  • The infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin regimen is associated with excellent results.
  • High-dose chemotherapy with autologous stem cell transplant is associated with long-term, disease-free survival in approximately 50-80% of patients with relapsed/refractory AIDS-lymphoma.
  • Addition of rituximab is associated with improved response rates, without an increase in infections.
  • Infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin is associated with excellent results among patients with either diffuse large B cell lymphoma or Burkitt's lymphoma.
  • Optimal therapy for patients with HIV-Hodgkin's lymphoma has not yet been defined.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106654.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


46. Singh AS, Dave DJ, Thanvi S, Atre DA, Parikh P, Patel NH: Fatal secondary pulmonary hypertension due to cardiac involvement in AIDS-associated Burkitt's lymphoma. Indian J Med Sci; 2006 Sep;60(9):380-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal secondary pulmonary hypertension due to cardiac involvement in AIDS-associated Burkitt's lymphoma.
  • Primary cardiac lymphomas are rare lesions in children with acquired immunodeficiency syndrome (AIDS).
  • Most of them are high-grade Burkitt's or Burkitt-like lymphomas.
  • The clinical profile and operative and pathological findings of a 4-year-old boy with AIDS-associated Burkitt's lymphoma of the heart presenting with acute right heart failure and fatal secondary pulmonary hypertension is reported.
  • [MeSH-major] Burkitt Lymphoma / complications. Heart Neoplasms / complications. Hypertension, Pulmonary / etiology. Lymphoma, AIDS-Related / complications


47. Wagner-Johnston ND, Ambinder RF: Epstein-Barr virus-related lymphoproliferative disorders. Curr Hematol Malig Rep; 2007 Oct;2(4):249-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-related lymphoproliferative disorders.
  • EBV is associated with a variety of lymphomas and lymphoproliferative disorders.
  • In this review we provide an update of the relevant literature on EBV-associated lymphoproliferative disorders, with particular emphasis on epidemiology, pathogenesis, and novel treatment approaches.
  • [MeSH-major] Epstein-Barr Virus Infections. Lymphoma / virology. Lymphoproliferative Disorders / virology
  • [MeSH-minor] Adoptive Transfer. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Antiviral Agents / therapeutic use. Brain Neoplasms / radiotherapy. Brain Neoplasms / virology. Clinical Trials as Topic. Combined Modality Therapy. Herpesvirus 4, Human / isolation & purification. Herpesvirus 4, Human / pathogenicity. Humans. Immunocompromised Host. Immunologic Factors / administration & dosage. Immunologic Factors / therapeutic use. Immunosuppressive Agents / adverse effects. Immunotherapy. Lymphocyte Subsets / virology. Lymphoma, AIDS-Related / virology. Multicenter Studies as Topic. Organ Transplantation. Postoperative Complications / drug therapy. Postoperative Complications / epidemiology. Postoperative Complications / virology. RNA, Viral / analysis. Rituximab. Viral Proteins / analysis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1853-61 [16385563.001]
  • [Cites] J Immunol. 2006 Oct 1;177(7):4897-906 [16982932.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1504-9 [16705315.001]
  • [Cites] Int J Infect Dis. 2007 Mar;11(2):172-8 [16931088.001]
  • [Cites] Int J Hematol. 2006 Jan;83(1):66-73 [16443556.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] Am J Transplant. 2006 Aug;6(8):1906-12 [16889546.001]
  • [Cites] Eur J Immunol. 2006 Mar;36(3):593-602 [16479544.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2280-9 [16757686.001]
  • [Cites] Clin Transplant. 2006 May-Jun;20(3):389-93 [16824159.001]
  • [Cites] J Clin Virol. 2006 Aug;36(4):258-63 [16762591.001]
  • [Cites] Arch Dermatol. 2006 May;142(5):587-95 [16702496.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2620-30 [17507664.001]
  • [Cites] Blood. 2006 Jul 1;108(1):11-8 [16543467.001]
  • [Cites] Transplantation. 2006 Mar 27;81(6):856-61 [16570008.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):460-4 [16428487.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4626-33 [16954517.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4):596-604 [17379070.001]
  • [Cites] Blood. 2007 Mar 15;109 (6):2597-603 [17148591.001]
  • [Cites] Sao Paulo Med J. 2006 May 4;124(3):154-7 [17119693.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2382-8 [17332371.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3101-8 [17536082.001]
  • [Cites] Blood. 2006 Nov 1;108(9):2942-9 [16835376.001]
  • [Cites] J Dermatol Sci. 2007 Mar;45(3):153-60 [17169531.001]
  • [Cites] Clin Transplant. 2006 Nov-Dec;20(6):689-94 [17100717.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):60-6 [17058198.001]
  • [Cites] J Infect. 2006 Jun;52(6):e173-6 [16246422.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):92-100 [16360421.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3053-7 [16254143.001]
  • [Cites] Eur J Haematol. 2006 Feb;76(2):109-18 [16405431.001]
  • (PMID = 20425377.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antiviral Agents; 0 / Immunologic Factors; 0 / Immunosuppressive Agents; 0 / RNA, Viral; 0 / Viral Proteins; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 33
  •  go-up   go-down


48. Valencia ME: AIDS-related lymphomas--potentially curable in the HAART era. AIDS Rev; 2006 Apr-Jun;8(2):108-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphomas--potentially curable in the HAART era.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / complications. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Female. Hodgkin Disease / drug therapy. Humans. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Prognosis. Treatment Outcome


49. Goldstein MA, Naidich TP, Silverman ME: Clinical importance of delayed MRI contrast enhancement of primary central nervous system lymphoma in AIDS. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical importance of delayed MRI contrast enhancement of primary central nervous system lymphoma in AIDS.
  • Accurately distinguishing between cerebral toxoplasmosis and primary central nervous system lymphoma (PCNSL), still the most common secondary CNS mass lesion complications of AIDS, has long represented a diagnostic challenge in those with HIV.
  • A young adult male with AIDS presented with evolving ophthalmoplegias, Parinaud's syndrome and gait dysfunction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2003 Apr;24(4):554-5 [12695179.001]
  • [Cites] Neurology. 1998 Jan;50(1):21-6 [9443452.001]
  • (PMID = 21686485.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027744
  •  go-up   go-down


50. Dunleavy K, Wilson WH, Kaplan LD: The case for rituximab in AIDS-related lymphoma. Blood; 2006 Apr 1;107(7):3014-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The case for rituximab in AIDS-related lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Humans. Lymphoma, Non-Hodgkin / drug therapy. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • (PMID = 16554492.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


51. Hassan A, Kreisel F, Gardner L, Lewis JS Jr, El-Mofty SK: Plasmablastic lymphoma of head and neck: report of two new cases and correlation with c-myc and IgVH gene mutation status. Head Neck Pathol; 2007 Dec;1(2):150-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma of head and neck: report of two new cases and correlation with c-myc and IgVH gene mutation status.
  • Plasmablastic lymphoma (PBL) is a rare acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma (AIDS-NHL), with predilection for the mucosa of oral cavity.
  • It usually has a plasmablastic morphology, expressing plasma cell-associated antigens with weak or absent expression of B-cell-associated markers.
  • To further define the immunophenotypic and molecular genetics of these tumors, we investigated two cases of plasmablastic lymphomas of the head and neck for c-myc gene rearrangement and immunoglobulin heavy chain (IgV(H)) hypermutation status.
  • For the first time we report a case of AIDS-related PBL that, by fluorescence in situ hybridization (FISH), shows a c-myc gene rearrangement.
  • Although current literature suggests that most cases of c-myc gene rearranged AIDS-NHL are Burkitt's lymphoma, our case has an immunophenotype characteristic for PBL.
  • The concurrent B-cell immunophenotype of BCL-6(-)/CD138(+)/MUM-1(+) also suggests a post-germinal center B-cell origin of this lymphoma.
  • [MeSH-major] Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Mouth Neoplasms / pathology. Proto-Oncogene Proteins c-myc / genetics

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):77-81 [15621784.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):806-15 [15578069.001]
  • [Cites] Cancer. 2005 Jun 25;105(3):139-44 [15803491.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Aug;100(2):198-206 [16037778.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):96-102 [11755827.001]
  • [Cites] Hum Pathol. 2002 Apr;33(4):392-404 [12055673.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]
  • [Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3928-32 [14581416.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):95-100 [9709310.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Blood. 1993 Jan 1;81(1):166-76 [8380252.001]
  • [Cites] Blood. 1993 Jul 15;82(2):552-63 [8392399.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Semin Diagn Pathol. 1997 Feb;14(1):67-82 [9044511.001]
  • (PMID = 20614267.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ PMC2807524
  • [Keywords] NOTNLM ; Acquired immunodeficiency syndrome-associated non-Hodgkin’s lymphoma / Immunoglobulin variable heavy chain hypermutation status / Plasmablastic lymphoma / c-myc gene rearrangement
  •  go-up   go-down


52. Castillo J, Perez K, Milani C, Dezube BJ, Pantanowitz L: Peripheral T-cell lymphomas in HIV-infected individuals: a comprehensive review. J HIV Ther; 2009 Jun;14(2):34-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphomas in HIV-infected individuals: a comprehensive review.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, T-Cell, Peripheral / pathology

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19839365.001).
  • [ISSN] 1462-0308
  • [Journal-full-title] Journal of HIV therapy
  • [ISO-abbreviation] J HIV Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 87
  •  go-up   go-down


53. Shankar SK, Mahadevan A, Satishchandra P, Kumar RU, Yasha TC, Santosh V, Chandramuki A, Ravi V, Nath A: Neuropathology of HIV/AIDS with an overview of the Indian scene. Indian J Med Res; 2005 Apr;121(4):468-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuropathology of HIV/AIDS with an overview of the Indian scene.
  • Neurological manifestations of HIV infection and AIDS are being recognized with a frequency that parallels the increasing number of AIDS cases.
  • Next to sub-Saharan Africa, India has the second largest burden of HIV related pathology, essentially caused by HIV-1 clade C in both the geographic locales, in contrast to USA and Europe.
  • But the true prevalence of HIV related neuroinfections and pathology is not available due to inadequate medical facilities, social stigma and ignorance that lead to underdiagnosis.
  • Inspite of heavy burden of HIV/AIDS, HIV associated neoplasia is infrequent, including primary CNS lymphomas.
  • HIV encephalitis and HIV associated dementia are considered infrequent, though systematic studies have just been initiated in various centres.
  • Till now the AIDS cases in India were drug naive but a new cohort of cases following initiation of HAART therapy as a national policy is soon emerging, altering the biology and evolution of HIV/AIDS in India.
  • Lacunae in the epidemiology, diagnosis and study of biology of HIV/AIDS are outlined for future research.
  • [MeSH-major] Central Nervous System Neoplasms / complications. HIV Infections / physiopathology. Nervous System Diseases / complications

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15817957.001).
  • [ISSN] 0971-5916
  • [Journal-full-title] The Indian journal of medical research
  • [ISO-abbreviation] Indian J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] India
  • [Number-of-references] 153
  •  go-up   go-down


54. Keszler A, Piloni MJ, Paparella ML, Soler Mde D, Ron PC, Narbaitz M: Extranodal oral non-Hodgkin's lymphomas. A retrospective study of 40 cases in Argentina. Acta Odontol Latinoam; 2008;21(1):43-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal oral non-Hodgkin's lymphomas. A retrospective study of 40 cases in Argentina.
  • A retrospective study was conducted of extranodal oral Non-Hodgkin's Lymphomas diagnosed at the Surgical Pathology Laboratory of the School of Dentistry at Buenos Aires University, Argentina, between 1985 and 2004.
  • The most common histological type was Diffuse Large Cell Lymphoma.
  • 60% of the Plasmablastic Lymphomas in the series came from HIV+ patients.
  • [MeSH-major] Jaw Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Non-Hodgkin / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Argentina. Child. Child, Preschool. Female. Humans. Lymphoma, AIDS-Related / pathology. Male. Middle Aged. Retrospective Studies. Sex Distribution. Young Adult

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841745.001).
  • [ISSN] 0326-4815
  • [Journal-full-title] Acta odontológica latinoamericana : AOL
  • [ISO-abbreviation] Acta Odontol Latinoam
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Argentina
  •  go-up   go-down


55. Tanaka PY, Calore EE: P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients. Pathol Res Pract; 2007;203(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients.
  • It still needs to be clarified whether P-gp expression has a significant impact on non-Hodgkin's lymphoma treatment response, but a poor outcome has been reported in patients with positive P-gp expression.
  • AIDS-related lymphomas have aggressive behavior, and although a complete response could be achieved, relapse is not uncommon.
  • In an attempt to determine a possible relationship between MDR and poor outcome in this population, histologic samples obtained from 45 non-Hodgkin's lymphoma HIV-infected patients without previous cytotoxic therapy were submitted to immunohistochemical analysis using monoclonal antibody C494 specific for the MDR-1 isoform of P-gp.
  • In patients having achieved complete remission, the median disease-free survival (DFS) was not reached; the mean DFS was 57.2 months with DFS rates of 72.9% in three years.
  • Our results show that P-gp is expressed before treatment of non-Hodgkin's lymphoma of HIV patients, and is related to poor response to treatment and overall survival.
  • [MeSH-major] Acquired Immunodeficiency Syndrome. Lymphoma, AIDS-Related / metabolism. P-Glycoprotein / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / mortality. Biomarkers, Tumor / metabolism. Cell Count. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Retrospective Studies. Survival Rate. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathol Res Pract. 2007;203(10):763
  • (PMID = 17157997.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Biomarkers, Tumor; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


56. Dayyani F, Pantanowitz L, Sandridge TG, Sullivan RJ, Dezube BJ: Multicentric Castleman's disease masquerading as HIV-related lymphoma. Am J Med Sci; 2007 Oct;334(4):317-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric Castleman's disease masquerading as HIV-related lymphoma.
  • Patients with human immunodeficiency virus (HIV) infection are at increased risk for developing lymphoproliferative disorders.
  • Multicentric Castleman's disease should always be kept in the differential diagnosis of HIV-positive patients suspected of having lymphoma to avoid misdiagnosis.
  • We report the case of a 40-year-old HIV-positive homosexual man who presented with lower back pain and features highly suggestive of lymphoma including lymphadenopathy, elevated lactic dehydrogenase, and splenomegaly.
  • The patient's plasma was positive by polymerase chain reaction for Kaposi sarcoma herpesvirus/human herpesvirus-8 (KSHV/ HHV8), and a lymph node biopsy revealed Multicentric Castleman's disease.
  • Albeit a rare condition, Castleman's disease should always be considered in immunocompromised patients suspected of having lymphoma.
  • [MeSH-major] Giant Lymph Node Hyperplasia / diagnosis. Lymphoma, AIDS-Related / diagnosis


57. Carbone A, Gloghini A: KSHV/HHV8-associated lymphomas. Br J Haematol; 2008 Jan;140(1):13-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KSHV/HHV8-associated lymphomas.
  • This review looks at the current state of knowledge on primary effusion lymphoma (PEL) and other Kaposi sarcoma herpesvirus (KSHV)/human herpesvirus 8 (HHV8)-associated lymphomas.
  • In 1995, KSHV DNA sequences were identified within a distinct subgroup of acquired immunodeficiency syndrome-related non-Hodgkin lymphomas localized in body cavities and presenting as pleural, peritoneal and pericardial lymphomatous effusions.
  • Subsequently, the spectrum of KSHV/HHV8-associated lymphomas has been expanded by the identification of cases of extracavitary solid lymphomas without serous effusions.
  • Despite the diversification in the clinical presentation of KSHV/HHV8-associated lymphomas, the majority of the cases reported demonstrated similar morphology, immunophenotype and KSHV/HHV8 viral status.
  • KSHV/HHV8 infection is also in multicentric Castleman disease-associated plasmablastic lymphoma.
  • The prognosis for KSHV/HHV8-associated lymphomas is poor.
  • [MeSH-major] Herpesviridae Infections. Herpesvirus 8, Human. Lymphoma / virology
  • [MeSH-minor] Humans. Lymphoma, AIDS-Related / pathology. Lymphoma, AIDS-Related / therapy. Lymphoma, AIDS-Related / virology. Prognosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991301.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 105
  •  go-up   go-down


58. Shiels MS, Cole SR, Wegner S, Armenian H, Chmiel JS, Ganesan A, Marconi VC, Martinez-Maza O, Martinson J, Weintrob A, Jacobson LP, Crum-Cianflone NF: Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters. J Acquir Immune Defic Syndr; 2008 Aug 1;48(4):485-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters.
  • OBJECTIVE: To explore the impact of highly active antiretroviral therapy (HAART) on the prevention of AIDS-defining cancers relative to other AIDS-defining events.
  • DESIGN: Prospective cohort study using 2,121 HIV+ male seroconverters (median age: 28 years, 51% white/non-Hispanic) in the Tri-Service AIDS Clinical Consortium (n = 1694) and the Multicenter AIDS Cohort Study (n = 427).
  • METHODS: Poisson regression models, with calendar periods to represent antiretroviral therapy, were extended to analyze first incident AIDS-defining cancers and other first AIDS-defining events as competing risks.
  • RESULTS: Eighty-one AIDS-defining cancers (64 Kaposi sarcomas; 17 non-Hodgkin lymphomas) and 343 other AIDS events occurred during 14,483 person-years in 1990-2006.
  • The rate ratio of AIDS-defining cancers during the HAART calendar period was 0.26 (95% confidence limits: 0.15, 0.46) and of other AIDS-defining events was 0.28 (95% confidence limits: 0.21, 0.36) compared with the monotherapy/combination therapy calendar period, adjusting for age, infection duration, race, and cohort.
  • The association of HAART with decreased AIDS incidence seemed to be equal (interaction ratio = 0.95 (95% confidence limits: 0.51, 1.74) for AIDS-defining cancers and other AIDS-defining events.
  • CONCLUSIONS: In human immunodeficiency virus-infected men, HAART seems equally protective against first AIDS-defining cancers and other first AIDS-defining events.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 2002 Oct;31(5):951-8 [12435766.001]
  • [Cites] Epidemiology. 2000 Sep;11(5):550-60 [10955408.001]
  • [Cites] Lancet. 2003 Jul 5;362(9377):22-9 [12853195.001]
  • [Cites] Am J Epidemiol. 2003 Oct 1;158(7):687-94 [14507605.001]
  • [Cites] Lancet. 2003 Oct 18;362(9392):1267-74 [14575971.001]
  • [Cites] Comput Methods Programs Biomed. 2004 Jul;75(1):45-9 [15158046.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 21;96(14):1070-6 [15265968.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1380-4 [15494916.001]
  • [Cites] Biometrics. 1986 Mar;42(1):121-30 [3719049.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Stat Med. 1994 Oct 15-30;13(19-20):2127-39 [7846415.001]
  • [Cites] Biometrics. 1995 Jun;51(2):524-32 [7662841.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):65-70 [10534148.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Am J Epidemiol. 2000 Nov 15;152(10):923-33 [11092434.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] AIDS. 2001 Feb 16;15(3):347-55 [11273215.001]
  • [Cites] J Infect. 2001 Feb;42(2):134-9 [11531320.001]
  • [Cites] Am J Epidemiol. 2001 Oct 1;154(7):675-81 [11581102.001]
  • [Cites] J Epidemiol Community Health. 2002 Feb;56(2):153-9 [11812817.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 May 1;30(1):81-7 [12048367.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 May 1;30(1):111-8 [12048371.001]
  • [Cites] N Engl J Med. 1997 Sep 11;337(11):725-33 [9287227.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):543-9 [9492772.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1497-503 [9809730.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41 [10430217.001]
  • [Cites] AIDS. 1999 Oct 1;13(14):1933-42 [10513653.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):378-84 [16054937.001]
  • [Cites] AIDS. 2005 Nov 18;19(17):2009-18 [16260908.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):194-200 [16394852.001]
  • [Cites] Am J Epidemiol. 2006 Feb 15;163(4):310-5 [16371516.001]
  • [Cites] AIDS. 2006 Jul 13;20(11):1531-8 [16847408.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] HIV Med. 2006 Sep;7(6):369-77 [16903981.001]
  • [Cites] Stat Med. 2007 May 20;26(11):2389-430 [17031868.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):142-4 [12455069.001]
  • (PMID = 18614916.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI035042-11; United States / NIAID NIH HHS / AI / HU0001-05-2-0011; United States / NIAID NIH HHS / AI / AI035041-10; United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NIDDK NIH HHS / DK / U01 DK066116; United States / NIAID NIH HHS / AI / AI035039-16; United States / NIAID NIH HHS / AI / UO1-AI-35042; United States / NIAID NIH HHS / AI / U01 AI035041-17; United States / NIAID NIH HHS / AI / UO1-AI-37984; United States / NIAID NIH HHS / AI / U01 AI035040-16; United States / NCI NIH HHS / CA / T32 CA009314-27S1; United States / NIAID NIH HHS / AI / UO1-AI-35040; United States / NIAID NIH HHS / AI / U01 AI035039-17; United States / NIAID NIH HHS / AI / AI037984-08; United States / NIAID NIH HHS / AI / U01 AI035043-11; United States / NIAID NIH HHS / AI / AI035039-17; United States / NIAID NIH HHS / AI / AI035043-10; United States / NIAID NIH HHS / AI / U01 AI035042-17; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NIAID NIH HHS / AI / U01 AI037613-08; United States / NIAID NIH HHS / AI / UO1-AI-35041; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NIAID NIH HHS / AI / AI035042-17; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIAID NIH HHS / AI / U01 AI037984-08; United States / NCI NIH HHS / CA / T32 CA009314-28S3; United States / PHS HHS / / HU0001-05-2-0011; None / None / / M01 RR000722-23; United States / NCI NIH HHS / CA / CA009314-26S1; United States / NIAID NIH HHS / AI / U01 AI035039-16; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / UO1-AI-35039; United States / NIAID NIH HHS / AI / AI037613-08; United States / NIAID NIH HHS / AI / U01 AI035041-10; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NCRR NIH HHS / RR / 5-MO1-RR-00722; United States / NCRR NIH HHS / RR / M01 RR000722-23; United States / NIAID NIH HHS / AI / U01 AI035043-10; United States / NCI NIH HHS / CA / T32 CA009314-26S1; United States / NCI NIH HHS / CA / CA009314-28S3; United States / NIAID NIH HHS / AI / U01 AI035039; United States / NIAID NIH HHS / AI / UO1-AI-35043; United States / NIAID NIH HHS / AI / UO1-AI-37613; United States / NCI NIH HHS / CA / T32 CA009314
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ NIHMS165363; NLM/ PMC2805176
  •  go-up   go-down


59. Martí-Carvajal AJ, Cardona AF, Lawrence A: Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma. Cochrane Database Syst Rev; 2009;(3):CD005419
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma.
  • BACKGROUND: Human immunodeficiency virus (HIV) infection is known to be associated with an increased risk of non-Hodgkin's lymphoma (NHL).
  • The majority of lymphomas (>80%) occurring during immunosuppression are aggressive B-cell in origin and have a high-to-intermediate histology grade.
  • OBJECTIVES: To assess the clinical effectiveness and safety of single agent or combination chemotherapy with or without immunochemotherapy (rituximab) and with or without highly active antiretroviral therapy (HAART) on overall survival (OS) and disease-free survival (DFS) for previously untreated patients with AIDS-related NHL.
  • For additional information see the Cochrane HIV/AIDS Group search strategy.
  • SELECTION CRITERIA: Randomized controlled trials (RCTs) assessing the effectiveness of systemic treatments for previously untreated AIDS-related NHL.
  • Disease free survival (DFS) was reported in two of the four RCTs, but it was not statistically significant between treatment groups.
  • AUTHORS' CONCLUSIONS: We found no evidence that the systemic interventions for untreated patients with AIDS-related NHL provide superior clinical effectiveness for improving OS, DSF, and tumour response rate; however, this conclusion is based on four RCTs with limited sample size and variable quality.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antiretroviral Therapy, Highly Active. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Prednisolone / administration & dosage. Prednisone / administration & dosage. Randomized Controlled Trials as Topic. Rituximab. Vincristine / administration & dosage. Vindesine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19588373.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 11056-06-7 / Bleomycin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q573I9DVLP / Leucovorin; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; LNH 87 protocol; M-BACOD protocol; VAP-cyclo protocol
  • [Number-of-references] 112
  •  go-up   go-down


60. Lather N, Islam M, Fergus IV: Symptomatic metastatic right atrial lymphoma in a patient with AIDS presenting with pulmonary embolization. Rev Cardiovasc Med; 2008;9(4):275-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptomatic metastatic right atrial lymphoma in a patient with AIDS presenting with pulmonary embolization.
  • Secondary lymphoma with localization to the heart is the third most common malignant heart tumor and is more common, by far, than primary cardiac lymphomas.
  • In patients with human immunodeficiency virus, the risk of development of systemic lymphoma is 60 to 200 times higher than in the general population.
  • Transthoracic echocardiography is the initial modality of choice for diagnosis of cardiac lymphomas because it is readily available and helps localize the tumor, but transesophageal echocardiography and magnetic resonance imaging remain the best tests for evaluation.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Heart Atria / pathology. Heart Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Pulmonary Embolism / virology


61. Riedel DJ, Gonzalez-Cuyar LF, Zhao XF, Redfield RR, Gilliam BL: Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis; 2008 Apr;8(4):261-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection.
  • Plasmablastic lymphoma of the oral cavity is a form of non-Hodgkin lymphoma (NHL) and was first described in 1997.
  • We describe a case of plasmablastic lymphoma in an HIV-infected patient who presented with an expanding oral lesion and symptoms of a toothache.
  • We review all cases of plasmablastic lymphoma that have been reported in the literature.
  • Plasmablastic lymphoma is strongly associated with immunodeficiency, and most particularly, with HIV infection.
  • The pathophysiological origin of plasmablastic lymphoma has not been fully characterised, but the presence of Epstein-Barr virus (EBV) has often been documented in biopsy specimens, supporting a role for EBV in the pathogenesis of this lymphoma.
  • Infectious disease clinicians should be aware of this newly described and increasingly encountered lymphoma, since it is prominently associated with immunosuppression and may be mistaken for other entities.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Mouth / pathology. Mouth Neoplasms / diagnosis
  • [MeSH-minor] Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Biopsy. Diagnosis, Differential. Head / radiography. Humans. Male. Tomography, X-Ray Computed. Toothache / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Lancet Infect Dis. 2010 Apr;10(4):226
  • (PMID = 18353267.001).
  • [ISSN] 1473-3099
  • [Journal-full-title] The Lancet. Infectious diseases
  • [ISO-abbreviation] Lancet Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


62. Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M, Spina M, Manuele R, Vaccher E, Mazzucato M, Abbruzzese L, Ferremi P, Carosi G, Tirelli U, Rossi G: High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood; 2009 Aug 13;114(7):1306-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors.
  • After the introduction of highly active antiretroviral therapy (HAART), intensive treatment, including high-dose therapy (HDT) and peripheral blood stem cell transplantation (PBSCT), has become feasible in HIV-positive patients with Hodgkin (HL) and non-Hodgkin (NHL) lymphoma.
  • Herein, we report the long-term results, on an intention-to-treat basis, of a prospective study on HDT and PBSCT in 50 HIV-positive HAART-responding patients with refractory/relapsed lymphoma.
  • After debulking therapy, 2 patients had early toxic deaths, 10 had chemoresistant disease, 6 failed stem cell mobilization, 1 refused collection, and 4 progressed soon after PBSC harvest.
  • Twenty-one patients are alive and disease-free after a median follow-up of 44 months (OS, 74.6%; PFS, 75.9%).
  • Only lymphoma response significantly affected OS after transplantation.
  • In multivariate analyses both lymphoma stage and low CD4 count negatively influenced the possibility to receive transplant.
  • PBSCT is a highly effective salvage treatment for chemosensitive AIDS-related lymphoma.
  • It seems rational to explore its use earlier during the course of lymphoma to increase the proportion of patients who can actually receive transplant.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / therapy. Antiretroviral Therapy, Highly Active. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. CD4 Lymphocyte Count. Disease-Free Survival. Female. Follow-Up Studies. Humans. Italy. Male. Middle Aged. Salvage Therapy / methods. Survival Rate. Transplantation, Autologous


63. Krishnan A, Molina A, Zaia J, Smith D, Vasquez D, Kogut N, Falk PM, Rosenthal J, Alvarnas J, Forman SJ: Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood; 2005 Jan 15;105(2):874-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas.
  • The treatment of HIV-associated lymphoma has changed since the widespread use of highly active antiretroviral therapy.
  • HIV-infected individuals can tolerate more intensive chemotherapy, as they have better hematologic reserves and fewer infections.
  • This has led to higher response rates in patients with HIV-associated Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL) treated with chemotherapy in conjunction with antiretroviral therapy.
  • However, for patients with refractory or relapsed disease, salvage chemotherapy still offers little chance of long-term survival.
  • In the non-HIV setting, patients with relapsed Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL) have a better chance of long-term remission with high-dose chemotherapy with autologous stem cell rescue (ASCT) compared with conventional salvage chemotherapy.
  • In a prior report we demonstrated that this approach is well tolerated in patients with underlying immunodeficiency from HIV infection.
  • Furthermore, similar engraftment to the non-HIV setting and low infectious risks have been observed.
  • With long-term follow-up we demonstrate that ASCT can lead to an 85% progression-free survival, which suggests that this approach may be potentially curative in select patients with relapsed HIV-associated HD or NHL.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. CD4 Lymphocyte Count. Child. Disease-Free Survival. Follow-Up Studies. Humans. Middle Aged. Recurrence. Remission Induction. Risk Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15388574.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI38592; United States / NCI NIH HHS / CA / CA30206; United States / NCI NIH HHS / CA / CA33572
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


64. Miralles P, Berenguer J, Ribera Santasusana JM, Calvo F, Díaz Mediavilla J, Díez-Martín JL, Gomez Codina J, López Aldeguer J, Rubio R, Santos J, Valencia E: [GESIDA/PETHEMA guidelines for the diagnosis and treatment of lymphomas in HIV-infected patients]. Med Clin (Barc); 2008 Mar 8;130(8):300-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [GESIDA/PETHEMA guidelines for the diagnosis and treatment of lymphomas in HIV-infected patients].
  • [Transliterated title] Recomendaciones de GESIDA/PETHEMA sobre el diagnóstico y el tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / therapy. Practice Guidelines as Topic
  • [MeSH-minor] AIDS-Related Opportunistic Infections / prevention & control. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18358123.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 89
  •  go-up   go-down


65. Díez-Martín JL, Balsalobre P, Re A, Michieli M, Ribera JM, Canals C, Conde E, Rosselet A, Gabriel I, Varela R, Allione B, Cwynarski K, Genet P, Espigado I, Biron P, Schmitz N, Hunter AE, Ferrant A, Guillerm G, Hentrich M, Jurado M, Fernández P, Serrano D, Rossi G, Sureda A, European Group for Blood and Marrow Transplantation Lymphoma Working Party: Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood; 2009 Jun 4;113(23):6011-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation.
  • Autologous stem cell transplantation (ASCT) has been successfully used in HIV-related lymphoma (HIV-Ly) patients on highly active antiretroviral therapy.
  • We report the first comparative analysis between HIV-Ly and a matched cohort of HIV(-) lymphoma patients.
  • This retrospective European Group for Blood and Marrow Transplantation study included 53 patients (66% non-Hodgkin and 34% Hodgkin lymphoma) within each cohort.
  • Both groups were comparable except for the higher proportion of males, mixed-cellularity Hodgkin lymphoma and patients receiving granulocyte colony-stimulating factor before engraftment and a smaller proportion receiving total body irradiation-based conditioning within the HIV-Ly cohort.
  • A higher nonrelapse mortality within the first year after ASCT was observed in the HIV-Ly group (8% vs 2%), predominantly because of early bacterial infections, although this was not statistically significant and did not influence survival.
  • Thus, within the highly active antiretroviral therapy era, HIV patients should be considered for ASCT according to the same criteria adopted for HIV(-) lymphoma patients.
  • [MeSH-major] HIV Infections / surgery. Hodgkin Disease / surgery. Peripheral Blood Stem Cell Transplantation


66. Wong HL, Breen EC, Pfeiffer RM, Aissani B, Martinson JJ, Margolick JB, Kaslow RA, Jacobson LP, Ambinder RF, Chanock S, Martínez-Maza O, Rabkin CS: Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study. AIDS; 2010 Apr 24;24(7):1025-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study.
  • BACKGROUND: Cytokine stimulation of B-cell proliferation may be an important causative mechanism for acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin lymphoma (NHL).
  • The Epstein-Barr virus (EBV) may be a co-factor, particularly for primary central nervous system (CNS) tumors, which are uniformly EBV-positive in the setting of AIDS.
  • Thus, we examined associations of genetic variation in IL10 and related cytokine-signaling molecules (IL10RA, CXCL12, IL13, IL4, IL4R, CCL5 and BCL6) with AIDS-related NHL risk and evaluated differences between primary CNS and systemic tumors.
  • PATIENTS AND MATERIALS: We compared 160 Multicenter AIDS Cohort Study (MACS) participants with incident lymphomas, of which 90 followed another AIDS diagnosis, to HIV-1-seropositive controls matched on duration of lymphoma-free survival post-HIV-1 infection (N = 160) or post-AIDS diagnosis (N = 90).
  • RESULTS: Carriage of at least one copy of the T allele for the IL10 rs1800871 (as compared to no copies) was associated with decreased AIDS-NHL risk specific to lymphomas arising from the CNS (CC vs. CT/TT: OR = 0.3; 95% CI 0.1, 0.7) but not systemically (CC vs. CT/TT: OR = 1.0; 95% CI 0.5, 1.9) (Pheterogeneity = 0.03).
  • Carriage of two copies of the 'low IL10' haplotype rs1800896_A/rs1800871_T/rs1800872_A was associated with decreased lymphoma risk that varied by number of copies (Ptrend = 0.02).
  • CONCLUSION: Excessive IL10 response to HIV-1 infection may be associated with increased risk of NHL, particularly in the CNS.
  • IL10 dysregulation may be an important causative pathway for EBV-related lymphomagenesis.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2000 Mar;181(3):872-80 [10720507.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3325-30 [11013271.001]
  • [Cites] EMBO J. 2000 Dec 15;19(24):6742-50 [11118209.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14467-72 [11121048.001]
  • [Cites] Arthritis Rheum. 2001 Jan;44(1):176-9 [11212157.001]
  • [Cites] J Infect Dis. 2001 Sep 15;184(6):777-80 [11517440.001]
  • [Cites] Pharmacol Ther. 2002 Sep;95(3):295-304 [12243799.001]
  • [Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]
  • [Cites] Immunogenetics. 2003 Dec;55(9):629-32 [14605776.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]
  • [Cites] Science. 1990 Jun 8;248(4960):1230-4 [2161559.001]
  • [Cites] Science. 1990 Nov 9;250(4982):830-2 [2173142.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Lancet. 1991 Oct 19;338(8773):969-73 [1681341.001]
  • [Cites] Blood. 1993 Jan 1;81(1):166-76 [8380252.001]
  • [Cites] Br J Haematol. 1995 Jun;90(2):235-43 [7794745.001]
  • [Cites] Clin Exp Allergy. 1995 Nov;25 Suppl 2:74-8; discussion 95-6 [8590350.001]
  • [Cites] J Natl Cancer Inst. 1996 May 15;88(10):675-9 [8627644.001]
  • [Cites] Acta Haematol. 1996;95(3-4):193-8 [8677742.001]
  • [Cites] Ann Intern Med. 1997 Jun 15;126(12):946-54 [9182471.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):143-9 [9792301.001]
  • [Cites] J Immunol. 1999 Feb 1;162(3):1827-35 [9973448.001]
  • [Cites] Arthritis Rheum. 1999 Jun;42(6):1101-8 [10366102.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2928-35 [16332968.001]
  • [Cites] JAMA. 2006 Sep 27;296(12):1498-506 [17003398.001]
  • [Cites] Genes Immun. 2006 Dec;7(8):615-24 [16971956.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):704-12 [17056605.001]
  • [Cites] Leuk Lymphoma. 2007 Nov;48(11):2235-8 [17990180.001]
  • [ErratumIn] AIDS. 2010 Jul 31;24(12):1973
  • (PMID = 20299965.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NCRR NIH HHS / RR / 5-M01-RR-00722; United States / NIAID NIH HHS / AI / UO1-AI-35042; United States / NCI NIH HHS / CA / R01 CA073475; United States / NIAID NIH HHS / AI / UO1-AI-37984; United States / NIAID NIH HHS / AI / UO1-AI-35040; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NIAID NIH HHS / AI / UO1-AI-35041; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NCI NIH HHS / CA / P50-CA-096888; United States / NCI NIH HHS / CA / R01-CA57152; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NCI NIH HHS / CA / R01 CA057152; United States / Intramural NIH HHS / / Z99 CA999999; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / UO1-AI-35039; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NIAID NIH HHS / AI / U01 AI035039; United States / NCI NIH HHS / CA / P50 CA096888; United States / NIAID NIH HHS / AI / UO1-AI-35043; United States / NIAID NIH HHS / AI / UO1-AI-37613; United States / NCI NIH HHS / CA / R01-CA73475
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 130068-27-8 / Interleukin-10
  • [Other-IDs] NLM/ NIHMS192123; NLM/ PMC3950937
  •  go-up   go-down


67. Wong KH, Lee SS, Chan KC: Twenty years of clinical human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) in Hong Kong. Hong Kong Med J; 2006 Apr;12(2):133-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twenty years of clinical human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) in Hong Kong.
  • OBJECTIVE: To elucidate the development of human immunodeficiency virus (HIV) clinical care and research in Hong Kong.
  • DATA SOURCES: Articles on clinical HIV and acquired immunodeficiency syndrome (AIDS) published from 1985 to 2004 were identified through four sources: Red Ribbon Centre, Special Preventive Programme, Secretariat of the Scientific Committee on AIDS, and PubMed search.
  • STUDY SELECTION: Key words for the literature search were 'AIDS', 'HIV', and 'Hong Kong'.
  • The contents were catalogued under seven areas: clinical epidemiology, HIV disease course and presentation, specific complications or organ-based manifestations, immunological evaluation and other monitoring, antiretroviral therapy, HIV/AIDS mortality, and HIV in specific groups.
  • Prevalence of HIV has remained low in Hong Kong but new infections continue to occur together with a significant number of late presenters.
  • Three published AIDS patients' series, up to the first 200 reported cases, identified Pneumocystis carinii pneumonia as the most common AIDS-defining illness in Hong Kong.
  • Local studies of Kaposi's sarcoma and HIV-associated lymphoma have also been reported.
  • Research on CD4 counts has revealed that it is lower in healthy and HIV-infected Chinese than their western counterparts.
  • Children, pregnant women, and haemophiliac patients infected with HIV are among the specific groups of patients studied.
  • Survival of patients with advanced disease has greatly improved over the years, particularly after the advent of highly active antiretroviral therapy.
  • CONCLUSION: The clinical presentation and outcome of HIV/AIDS patients in Hong Kong are a mixture of those of western and developing countries.
  • Research on clinical HIV/AIDS in Hong Kong is not only beneficial to the planning of patient care, but also enables the formulation of treatment guidelines and provides a reference for other countries.


68. Folk GS, Abbondanzo SL, Childers EL, Foss RD: Plasmablastic lymphoma: a clinicopathologic correlation. Ann Diagn Pathol; 2006 Feb;10(1):8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma: a clinicopathologic correlation.
  • Plasmablastic lymphoma (PBL) is an uncommon, recently described B-cell-derived lymphoma that displays distinctive affinity for extranodal presentation in the oral cavity.
  • Plasmablastic lymphoma is strongly associated with human immunodeficiency virus (HIV) infection, but has been reported in HIV-negative individuals.
  • Plasmablastic lymphoma may be poorly recognized by pathologists, which is partly attributable to its relatively rare occurrence and unusual immunophenotype.
  • Five cases of oral cavity lymphomas conforming to the current World Health Organization morphological criteria for PBL were retrieved from the consultation files at the Armed Forces Institute of Pathology.
  • Follow-up revealed only 1 patient alive with no evidence of disease.
  • Our cases show that PBL is an aggressive type of B-cell lymphoma predominantly found in the oral cavity.
  • Plasmablastic lymphoma is often associated with HIV infection.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, B-Cell / pathology. Mouth / pathology. Mouth Neoplasms / pathology. Plasma Cells / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16414538.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


69. Wolf T, Brodt HR, Fichtlscherer S, Mantzsch K, Hoelzer D, Helm EB, Mitrou PS, Chow KU: Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma; 2005 Feb;46(2):207-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART).
  • Non-Hodgkin's lymphoma is an AIDS-defining disease.
  • We collected data of 214 cases of AIDS-related Lymphoma (ARL) treated at our centre from January 1984 until May 2003 and analysed them using the Kaplan-Meier-, log rank- and Cox proportional hazard-model.
  • The incidence of AIDS-related primary CNS lymphomas (PCNSL) took a comparable, yet more pronounced development.
  • Using the univariate Kaplan-Meier analysis prolonged survival was significantly associated with the achievement of a complete remission as well as with a favourable virological response to HAART.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621803.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


70. Krishnan A, Forman SJ: Hematopoietic stem cell transplantation for AIDS-related malignancies. Curr Opin Oncol; 2010 Sep;22(5):456-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for AIDS-related malignancies.
  • PURPOSE OF REVIEW: AIDS-related malignancies are an ongoing cause of mortality in individuals with HIV infection.
  • In the HIV-negative setting, high-dose chemotherapy or stem cell transplantation is an option for patients with hematologic malignancies.
  • Prior to the advent of effective HIV therapy, stem cell transplantation was not feasible for HIV-positive patients.
  • The purpose of this article is to explore the transplant options for HIV-positive patients after widespread use of highly active antiretroviral therapy.
  • RECENT FINDINGS: Early autologous stem cell transplantation has studies had high relapse rates but they demonstrated that mobilization and engraftment of autologous stem cells were possible in AIDS patients.
  • Recently, in less advanced AIDS lymphoma, autologous stem cell transplantation has resulted in low transplant-related mortality and durable remissions.
  • In addition, case-control studies of HIV-positive versus HIV-negative lymphoma patients undergoing autologous stem cell transplantation have shown similar transplant-related mortality and overall survival.
  • The feasibility of allogeneic stem cell transplantation in HIV-infected individuals is less tested.
  • SUMMARY: The potential future applications of autologous and allogeneic stem cell transplantation are the cure of the malignancy as well as the underlying HIV infection by either transplantation of naturally resistant or genetically modified stem cells.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Jul 25;347(4):284-7 [12140307.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1306-13 [19451551.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] Blood. 1989 Apr;73(5):1340-50 [2649174.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]
  • [Cites] Bone Marrow Transplant. 1996 Dec;18(6):1195-7 [8971396.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3561-4 [10446961.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66 [18158962.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3484-7 [18698002.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2192-8 [19332732.001]
  • [Cites] Blood. 2009 Jun 4;113(23):6011-4 [19307667.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1521-9 [12824790.001]
  • (PMID = 20639760.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P50 CA107399
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS427480; NLM/ PMC3537514
  •  go-up   go-down


71. Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson JO, Bernasconi E, Terziroli B, Moirandat-Rytz S, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher HC, Battegay M, Koller MT, Swiss HIV Cohort Study: Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antivir Ther; 2007;12(6):931-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
  • OBJECTIVE: To assess the characteristics of combination antiretroviral therapy (cART) administered concomitantly with chemotherapy and to establish prognostic determinants of patients with AIDS-related non-Hodgkin's lymphoma.
  • METHODS: The study included 91 patients with AIDS-related non-Hodgkin's lymphoma from the Swiss HIV Cohort Study enrolled between January 1997 and October 2003, excluding lymphomas of the brain.
  • We extracted AIDS-related non-Hodgkin's lymphoma- and HIV-specific variables at the time of lymphoma diagnosis as well as treatment changes over time from charts and from the Swiss HIV Cohort Study database.
  • Thirty-five patients stopped chemotherapy prematurely (before the sixth cycle) usually due to disease progression; these patients had a shorter median survival than those who completed six or more cycles (14 versus 28 months).
  • Factors associated with overall survival were CD4+ T-cell count (<100 cells/microl) (hazard ratio [HR] 2.95 [95% confidence interval (CI) 1.53-5.67], hepatitis C seropositivity (HR 2.39 [95% CI 1.01-5.67]), the international prognostic index score (HR 1.98-3.62 across categories) and Burkitt histological subtypes (HR 2.56 [95% CI 1.13-5.78]).
  • The effect of cART interruptions on AIDS-related non-Hodgkin's lymphoma prognosis remains unclear, however, hepatitis C seropositivity emerged-as a predictor of death beyond the well-known international prognostic index score and CD4+ T-cell count.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy


72. Simonelli C, Tedeschi R, Gloghini A, Talamini R, Bortolin MT, Berretta M, Spina M, Morassut S, Vaccher E, De Paoli P, Carbone A, Tirelli U: Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection. J Med Virol; 2009 May;81(5):888-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection.
  • This is a mono-institutional analysis of the clinical features, immunological and virological findings, and prognostic factors of patients with HIV infection and HHV-8-lymphoproliferative disorders.
  • Patients with Multicentric Castleman Disease and HHV-8-related lymphoma diagnosed and treated from April 1987 to June 2004 were included in the study.
  • HHV-8 and HIV plasma viral load, CD4+ count, hematologic parameters, and general wellbeing (performance status) were assessed at the onset of the diseases and analyzed in order to identify possible prognostic factors.
  • Nine patients with Multicentric Castleman disease, and 16 with HHV-8-related lymphomas (13 primary effusion lymphomas and 3 solid lymphomas), were diagnosed and treated out of 327 HIV-related non-Hodgkin's lymphomas.
  • Four patients with Multicentric Castleman disease received only antiretroviral drugs; 5 HAART plus oral etoposide.
  • Nine patients with primary effusion lymphoma were treated with a CHOP-like regimen (Cyclophosphamide, Prednisone anthracyclines, Vinca alkaloids, Bleomycin, Etoposide) and HAART; 1 with etoposide and HAART, 1 with HAART alone.
  • The patients with solid lymphoma underwent CHOP-like chemotherapy.
  • Patients with Multicentric Castleman disease showed lower median values of HHV-8 viral load and longer overall survival compared with HHV-8-related lymphomas.
  • In the univariate analysis, HHV-8-related lymphoma, HHV-8 viral load >40,000 cp/ml and performance status >2 were associated with an increased risk of death.
  • Multivariate analysis confirmed the diagnosis of lymphoma as an independent predictor of shorter survival.
  • [MeSH-major] HIV Infections / complications. Herpesviridae Infections / complications. Herpesvirus 8, Human / physiology. Lymphoma, AIDS-Related / drug therapy. Lymphoproliferative Disorders / complications. Viral Load
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. DNA, Viral / blood. Female. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / diagnosis. Giant Lymph Node Hyperplasia / drug therapy. Giant Lymph Node Hyperplasia / virology. Humans. Lymphoma / complications. Lymphoma / diagnosis. Lymphoma / drug therapy. Lymphoma / virology. Lymphoma, Primary Effusion / complications. Lymphoma, Primary Effusion / diagnosis. Lymphoma, Primary Effusion / drug therapy. Lymphoma, Primary Effusion / virology. Male. Middle Aged. Prognosis. Survival Analysis. Survival Rate. Treatment Outcome. Young Adult


73. Xu D, Coleman T, Zhang J, Fagot A, Kotalik C, Zhao L, Trivedi P, Jones C, Zhang L: Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas. J Virol; 2007 Jun;81(11):6068-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas.
  • The majority of AIDS-associated primary effusion lymphomas (PEL) are latently infected with both Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV).

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] J Virol. 2003 Aug;77(15):8532-40 [12857922.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5150-63 [12910252.001]
  • [Cites] J Virol. 2003 Sep;77(17):9451-62 [12915560.001]
  • [Cites] Gene. 2003 Oct 16;316:137-41 [14563560.001]
  • [Cites] Blood. 2004 Jan 1;103(1):313-6 [12969959.001]
  • [Cites] Virology. 2004 Jan 20;318(2):542-55 [14972523.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):46335-42 [15322136.001]
  • [Cites] Int J Cancer. 1977 Jan;19(1):27-33 [188769.001]
  • [Cites] J Virol. 1980 Nov;36(2):506-18 [6253674.001]
  • [Cites] J Virol. 1985 Sep;55(3):710-20 [2991591.001]
  • [Cites] Cell. 1985 Dec;43(3 Pt 2):831-40 [3000618.001]
  • [Cites] Virology. 1985 Mar;141(2):221-34 [3002016.001]
  • [Cites] J Virol. 1986 Apr;58(1):233-7 [3005654.001]
  • [Cites] J Gen Virol. 1987 Jun;68 ( Pt 6):1575-86 [2438376.001]
  • [Cites] Virology. 1987 Jul;159(1):161-5 [3037776.001]
  • [Cites] J Virol. 1990 Apr;64(4):1855-8 [2157069.001]
  • [Cites] J Virol. 1990 May;64(5):2126-34 [2157875.001]
  • [Cites] J Virol. 1990 May;64(5):2309-18 [2157887.001]
  • [Cites] J Virol. 1990 Jul;64(7):3407-16 [2352328.001]
  • [Cites] J Virol. 1990 Nov;64(11):5441-7 [2170681.001]
  • [Cites] Cell. 1991 Jun 28;65(7):1107-15 [1648447.001]
  • [Cites] J Virol. 1991 Dec;65(12):6765-71 [1658373.001]
  • [Cites] J Virol. 1992 Aug;66(8):5030-9 [1321285.001]
  • [Cites] J Virol. 1993 Aug;67(8):4651-8 [8392605.001]
  • [Cites] J Virol. 1993 Nov;67(11):6768-77 [8411380.001]
  • [Cites] EMBO J. 2000 Jun 15;19(12):3080-9 [10856251.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] J Virol. 2001 Feb;75(4):1909-17 [11160690.001]
  • [Cites] J Virol. 2001 Aug;75(15):6786-99 [11435557.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] J Virol. 2001 Dec;75(24):12393-401 [11711629.001]
  • [Cites] J Virol. 2002 Feb;76(3):998-1003 [11773375.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):437-42 [11752411.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3124-8 [8874212.001]
  • [Cites] Infect Agents Dis. 1996 Oct;5(4):215-22 [8884366.001]
  • [Cites] J Virol. 1996 Dec;70(12):8653-9 [8970991.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] Virology. 1997 Jul 21;234(1):1-13 [9234942.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1186-91 [9242551.001]
  • [Cites] EMBO J. 1997 Oct 15;16(20):6131-40 [9359753.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1700-9 [9501091.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] Virology. 1999 Oct 25;263(2):436-49 [10544116.001]
  • [Cites] Proc Assoc Am Physicians. 1999 Nov-Dec;111(6):573-80 [10591086.001]
  • [Cites] J Virol. 2000 Feb;74(3):1061-8 [10627515.001]
  • [Cites] Leukemia. 2000 Feb;14(2):271-7 [10673744.001]
  • [Cites] J Virol. 2000 Mar;74(6):2550-7 [10684269.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6438-42 [11741976.001]
  • [Cites] J Virol. 2002 May;76(10):5000-13 [11967316.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9150-4 [8415670.001]
  • [Cites] J Virol. 1993 Dec;67(12):7648-53 [8230484.001]
  • [Cites] J Virol. 1994 May;68(5):3354-63 [8151794.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] J Virol. 1995 Jul;69(7):4390-8 [7769701.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] AIDS Res Hum Retroviruses. 1995 Oct;11(10):1241-5 [8573381.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1237-40 [8684008.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] Virology. 1996 Sep 1;223(1):29-40 [8806537.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):3216-23 [10082588.001]
  • [Cites] J Virol. 1999 Jul;73(7):5556-67 [10364304.001]
  • [Cites] J Virol. 1999 Sep;73(9):7271-7 [10438815.001]
  • [Cites] Virology. 1999 Sep 15;262(1):18-30 [10489337.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2004 Dec;78(23):12987-95 [15542650.001]
  • [Cites] J Virol. 2004 Dec;78(23):13028-36 [15542654.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Virol. 2005 May;79(9):5640-52 [15827179.001]
  • [Cites] J Virol. 2005 Nov;79(22):14383-91 [16254372.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1921-4 [16574866.001]
  • [Cites] J Biol Chem. 2006 Apr 7;281(14):9163-9 [16469740.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):401-9 [10830748.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] Nat Med. 2002 Jun;8(6):594-9 [12042810.001]
  • [Cites] J Virol. 2002 Aug;76(16):8252-64 [12134031.001]
  • [Cites] BMC Microbiol. 2002 Jul 23;2:20 [12137568.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] Virology. 2002 Aug 1;299(2):301-14 [12202233.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6337-44 [12414666.001]
  • [Cites] J Virol. 2003 Jan;77(1):600-23 [12477864.001]
  • [Cites] J Virol. 2003 Jan;77(2):1441-51 [12502859.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1905-12 [12411306.001]
  • [Cites] J Virol. 2003 Mar;77(6):3809-15 [12610155.001]
  • [Cites] J Virol. 2003 Apr;77(8):5000-7 [12663807.001]
  • (PMID = 17376914.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / T32 AI060547; United States / NCI NIH HHS / CA / R01 CA108951; United States / NIAID NIH HHS / AI / R21AI59132; United States / NIAID NIH HHS / AI / R21 AI059132; United States / NCRR NIH HHS / RR / P20RR15635; United States / NIAID NIH HHS / AI / U54 AI057160; United States / NCRR NIH HHS / RR / P20 RR015635; United States / NCI NIH HHS / CA / R01CA108951
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1900272
  •  go-up   go-down


74. Carbone A, Gloghini A, Vaccher E, Cerri M, Gaidano G, Dalla-Favera R, Tirelli U: Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma. J Mol Diagn; 2005 Feb;7(1):17-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma.
  • Kaposi's sarcoma-associated herpesvirus (KSHV), also termed human herpesvirus type 8, is consistently identified in Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman's disease.
  • Here we report four cases of KSHV-bearing solid lymphomas that occurred in AIDS patients (cases 1 to 3) and in a human immunodeficiency virus (HIV)-seronegative person (case 4).
  • Epstein-Barr virus was detected in two of the HIV-related cases.
  • All KSHV-positive solid lymphomas exhibited PEL-like cell morphology.
  • To investigate the relationship of these disorders to PEL and to other AIDS-associated diffuse large cell lymphomas, KSHV-positive solid lymphomas were tested for the expression of a set of genes that were previously shown by gene profiling analysis to define PEL tumor cells.
  • The results showed that expression of this set of genes in KSHV-positive lymphomas is similar to that of PEL but distinct from KSHV-negative AIDS-associated diffuse large cell lymphomas.
  • Because pathobiological features of KSHV-positive solid lymphomas closely mimic those of PEL, our results suggest that KSHV-positive solid lymphomas should be considered as a tissue-based variant of classical PEL, irrespective of HIV status.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Jan;13(1):77-85 [10658913.001]
  • [Cites] Am J Surg Pathol. 1999 Oct;23(10):1208-16 [10524521.001]
  • [Cites] Leuk Lymphoma. 1999 Oct;35(3-4):379-87 [10706463.001]
  • [Cites] AIDS. 2000 Aug 18;14(12):1675-88 [10985303.001]
  • [Cites] Adv Cancer Res. 2001;80:115-46 [11034542.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):32-8 [11227070.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] AIDS Patient Care STDS. 2002 Apr;16(4):139-45 [12015867.001]
  • [Cites] Hum Pathol. 2002 Aug;33(8):846-9 [12203218.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1363-7 [12360052.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] Mod Pathol. 2003 May;16(5):424-9 [12748248.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3775-85 [12907442.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):290-6 [15507667.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1202-16 [4031967.001]
  • [Cites] N Engl J Med. 1993 Feb 4;328(5):327-35 [8093551.001]
  • [Cites] Lancet. 1993 Feb 13;341(8842):441 [8094208.001]
  • [Cites] EMBO J. 1993 Dec 15;12(13):4955-67 [8262038.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] AIDS. 1996 Aug;10(9):941-9 [8853726.001]
  • [Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]
  • [Cites] Int J Cancer. 1997 Oct 9;73(2):303-4 [9335459.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):165-74 [10343068.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):992-4 [10435572.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • (PMID = 15681470.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA037295; United States / NCI NIH HHS / CA / R37 CA037295; United States / NCI NIH HHS / CA / CA-37295
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1876263
  •  go-up   go-down


75. Fellner MD, Durand K, Correa RM, Redini L, Yampolsky C, Colobraro A, Sevlever G, Teyssié AR, Benetucci J, Picconi MA: Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma. Int J Infect Dis; 2007 Mar;11(2):172-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma.
  • OBJECTIVE: To analyze Epstein-Barr virus (EBV) load at different HIV infection stages and its relation with brain lymphoma.
  • DESIGN: A cross-sectional study was conducted on 172 HIV-infected individuals: 62 asymptomatic HIV carriers (group A), 30 HIV progressors (group B), 73 AIDS patients (group C), seven AIDS patients with brain lymphoma (group C-BL); and 26 blood donors (group BD) as healthy carriers.
  • RESULTS: PBMC-EBV levels in HIV-infected patients were higher than in the blood donors (p<0.05).
  • Similar PBMC-EBV loads were seen in HIV-infected patients with CD4+ T cell counts higher than 50/mm(3) (p>0.05), while significantly lower levels were found in cases with less than 50 cells/mm(3) (p<0.05).
  • In all HIV-infected patients, plasma-EBV load was lower than, or similar to, PBMC-EBV load, unlike 2/7 HIV-positive brain lymphoma patients.
  • CONCLUSIONS: During HIV infection PBMC-EBV load rises in comparison to healthy carriers, but decreases when immunosuppression progresses and CD4+ T cell count becomes <50/mm(3).
  • Circulating EBV is mainly cell-associated in the HIV-infected population.
  • Neither PBMC-EBV nor plasma-EBV loads would be useful to diagnose brain lymphoma in AIDS patients.
  • [MeSH-major] Brain Neoplasms / virology. HIV Infections / virology. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16931088.001).
  • [ISSN] 1201-9712
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


76. Miles SA, McGratten M: Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma. J Clin Oncol; 2005 Jan 1;23(1):247-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
  • [MeSH-major] Agammaglobulinemia / chemically induced. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15625386.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


77. Noy A: Controversies in the treatment of Burkitt lymphoma in AIDS. Curr Opin Oncol; 2010 Sep;22(5):443-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies in the treatment of Burkitt lymphoma in AIDS.
  • PURPOSE OF REVIEW: The success of combined antiretroviral therapy (cART) has transformed HIV infection into a survivable chronic disease in developed countries.
  • Increasingly then, the risks of HIV associated cancers become paramount.
  • Burkitt lymphoma is one of the cancer subtypes highly disproportionately affecting HIV infected patients.
  • RECENT FINDINGS: Recent conference proceedings appear to corroborate early reports that intensive therapy of HIV-Burkitt lymphoma is feasible and effective.
  • Moreover, as breakthroughs in the pathogenesis of lymphoma in general and Burkitt lymphoma in particular suggest that HIV infection plays a significant role, the opportunity for targeted therapy based on differences in biology are wholly untapped.
  • SUMMARY: Advances are being made in HIV-Burkitt lymphoma, but future studies need to incorporate our expanding understanding of biology to improve efficacy and reduce toxicity, preferably by integrating a biologic approach to this curable disease.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1492-9 [11920506.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1196-205 [12973843.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):475-8 [14617009.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):667-76 [14770420.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Med Clin North Am. 1992 Jan;76(1):253-68 [1727539.001]
  • [Cites] Am J Clin Pathol. 1995 May;103(5):561-7 [7741100.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2 Suppl 4):33-9; discussion 45-8 [9578060.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1755-66 [18596745.001]
  • [Cites] Leukemia. 2009 Apr;23(4):807-10 [18987659.001]
  • [Cites] Curr Opin Oncol. 2009 Sep;21(5):462-8 [19620863.001]
  • [Cites] Clin Lymphoma Myeloma. 2009 Aug;9(4):307-10 [19717381.001]
  • [Cites] Swiss Med Wkly. 2009 Oct 3;139(39-40):564-70 [19838874.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 Jan;53(1):124-30 [19730109.001]
  • [Cites] Br J Haematol. 2010 Jan;148(2):245-55 [19832807.001]
  • [Cites] Int J Cancer. 2010 Apr 1;126(7):1732-9 [19810101.001]
  • [Cites] Blood. 2010 Apr 15;115(15):3008-16 [20023215.001]
  • [Cites] Blood. 2010 Apr 15;115(15):3017-24 [20130244.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • (PMID = 20683266.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA121947-03S4; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / U01 CA121947-03S4
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Other-IDs] NLM/ NIHMS237420; NLM/ PMC3415038
  •  go-up   go-down


78. Latta S, Myint ZW, Jallad B, Hamdi T, Alhosaini MN, Kumar DV, Kheir F: Primary central nervous system T-cell lymphoma in aids patients: case report and literature review. Curr Oncol; 2010 Oct;17(5):63-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system T-cell lymphoma in aids patients: case report and literature review.
  • According to the published data, most primary central nervous system lymphomas (PCNSLs) are B-cell lymphomas; primary T-cell lymphomas are rare.
  • Here, we present the case of a 43-year-old man with AIDS, not on highly active antiretroviral therapy, who presented with focal neurologic symptoms and was found on magnetic resonance imaging to have multiple brain lesions.
  • A biopsy showed T-cell lymphoma, and the patient was subsequently treated with whole-brain radiation, to marked clinical response.
  • Reported cases from the literature of primary T-cell PCNSL in AIDS patients are summarized in this review.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20975881.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2949374
  • [Keywords] NOTNLM ; Primary cns lymphoma / T cells / aids / non-Hodgkin lymphoma
  •  go-up   go-down


79. Dupéré-Minier G, Desharnais P, Bernier J: Involvement of tyrosine phosphatase CD45 in apoptosis. Apoptosis; 2010 Jan;15(1):1-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, it is involved in apoptosis induced by HIV-1.
  • CD45 defect is implicated in various diseases such as severe-combined immunodeficiency disease (SCID), acquired immunodeficiency syndrome (AIDS), lymphoma and multiple myelomas.
  • The understanding of the mechanisms by which CD45 regulates apoptosis would be very useful in disease treatment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856105.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


80. Cobo F, Talavera P, Busquier H, Concha A: CNK/T-cell brain lymphoma associated with Epstein-Barr virus in a patient with AIDS. Neuropathology; 2007 Aug;27(4):396-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNK/T-cell brain lymphoma associated with Epstein-Barr virus in a patient with AIDS.
  • We report a case of extranodal NK/T-cell lymphoma, nasal type, with exclusive cerebral localization in a patient with AIDS.
  • A diagnosis of extranodal NK/T-cell lymphoma was made and the patient died a few days later.
  • This case represents a very rare example of NK/T-cell lymphoma of the brain in a patient with AIDS.
  • The diagnosis of this kind of lymphomas requires a multimodality approach correlating clinical, morphological, immunophenotypic and molecular data.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Epstein-Barr Virus Infections / complications. Killer Cells, Natural / pathology. Lymphoma, AIDS-Related / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / pathology. Adult. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Brain Neoplasms / virology. Diagnosis, Differential. Gene Rearrangement, T-Lymphocyte. Hepatitis C / complications. Herpesvirus 4, Human / genetics. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Polymerase Chain Reaction


81. Navarro JT, Lloveras N, Ribera JM, Oriol A, Mate JL, Feliu E: The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica; 2005 May;90(5):704-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy.
  • In the era of highly active antiretroviral treatment (HAART), the prognosis of AIDS-related lymphomas might be similar to that of aggressive B-cell lymphomas in human immunodeficiency (HIV)-negative patients.
  • In this study we found that HIV-infected patients with diffuse large B-cell lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone (CHOP) and HAART showed a similar response rate to chemotherapy, disease-free survival and overall survival as those of HIV-negative patients receiving CHOP.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / mortality. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. HIV Seronegativity. Humans. Male. Prednisone / administration & dosage. Prognosis. Vincristine / administration & dosage


82. Martini M, Capello D, Serraino D, Navarra A, Pierconti F, Cenci T, Gaidano G, Larocca LM: Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas. J Infect; 2007 Mar;54(3):298-306
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas.
  • OBJECTIVE: The aim of this study was to determine the occurrence of polymorphic variants of EBV BamHI fragment Z (BZLF1) promoter zone Zp in tumor and non-tumor-associated EBV.
  • We characterized the Zp region in type A and type B EBV, infecting AIDS-related non-Hodgkin's lymphomas (AIDS-NHL) and non-malignant lymphoid tissues derived from HIV-positive patients and from healthy individuals.
  • METHODS: The Zp region was directly sequenced in 133 EBV-positive DNA samples: 63 AIDS-NHL (32 systemic AIDS-NHL and 31 AIDS-primary central nervous system lymphoma [AIDS-PCNSL]), 30 lymphoid tissues derived from HIV-positive individuals and 40 lymphoid samples derived from healthy individuals.
  • Zp-V3 was significantly associated with AIDS-PCNSL (P<0.001) and with systemic AIDS-NHL (P=0.007), in particular with AIDS-related immunoblastic lymphoma (P<0.001).
  • Moreover, in malignant samples, this variant was also significantly associated with type B EBV (P<0.001).
  • Finally, the new identified Zp-PV variant was isolated in 7 AIDS-PCNSL.
  • CONCLUSIONS: The frequency of polymorphisms in the regulatory zone of BZLF1 is different between malignant and non-malignant samples in AIDS patients and may identify EBV subtypes with different transforming activities, including those associated to the pathogenesis of B cell lymphoma.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / virology. DNA-Binding Proteins / genetics. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / genetics. Lymphoma / virology. Promoter Regions, Genetic. Trans-Activators / genetics. Viral Proteins / genetics
  • [MeSH-minor] DNA, Viral / genetics. Humans. Lymphoid Tissue / virology. Lymphoma, AIDS-Related / virology. Polymorphism, Genetic. Sequence Analysis, DNA. Statistics as Topic

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784778.001).
  • [ISSN] 1532-2742
  • [Journal-full-title] The Journal of infection
  • [ISO-abbreviation] J. Infect.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BZLF1 protein, Herpesvirus 4, Human; 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / Trans-Activators; 0 / Viral Proteins
  •  go-up   go-down


83. Baraboutis IG, Marinos L, Lekakis LJ, Papastamopoulos V, Georgiou O, Tsagalou EP, Rondogianni P, Apostolidis J, Papadaki T, Skoutelis AT: Long-term complete regression of nodal marginal zone lymphoma transformed into diffuse large B-cell lymphoma with highly active antiretroviral therapy alone in human immunodeficiency virus infection. Am J Med Sci; 2009 Dec;338(6):517-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term complete regression of nodal marginal zone lymphoma transformed into diffuse large B-cell lymphoma with highly active antiretroviral therapy alone in human immunodeficiency virus infection.
  • Since the introduction of combination antiretroviral therapy (cART), there has been a decrease in the incidence of non-Hodgkin lymphoma among the HIV-infected population and also significantly improved survival rates.
  • We describe a remarkable case of a HIV-infected patient whose large B-cell lymphoma, most likely arising by transformation of a nodal marginal zone lymphoma, completely regressed with the use of cART alone.
  • He remained disease-free for almost 3 years and he finally died from presumed flare up of his lymphoma.
  • There are very few cases of spontaneous regression of lymphomas with cART alone in the HIV population.
  • This is an extreme example of the significance of cART in improving survival in HIV-non-Hodgkin lymphoma and changing the face of the HIV epidemic in general.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, B-Cell, Marginal Zone / complications. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010159.001).
  • [ISSN] 1538-2990
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


84. Grogg KL, Miller RF, Dogan A: HIV infection and lymphoma. J Clin Pathol; 2007 Dec;60(12):1365-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV infection and lymphoma.
  • The incidence of lymphoma in patients with HIV infection greatly exceeds that of the general population.
  • The increased risk for lymphoma appears related to multiple factors, including the transforming properties of the retrovirus itself, the immunosuppression and cytokine dysregulation that results from the disease, and, most importantly, opportunistic infections with other lymphotrophic herpes viruses such as Epstein-Barr virus and human herpesvirus 8.
  • Histologically lymphomas fall into three groups:.
  • (2) those occurring more specifically in HIV-positive patients; and (3) those also occurring in patients with other forms of immunosuppression.
  • Aggressive lymphomas account for the vast majority cases.
  • They frequently present with advanced stage, bulky disease with high tumour burden and, typically, involve extranodal sites.
  • Clinical outcome appears to be worse than in similar aggressive lymphomas in the general population.
  • However, following the introduction of highly active antiretroviral therapy, the risk for developing lymphoma in the context of HIV infection has decreased and the clinical outcome has improved.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Burkitt Lymphoma / immunology. Burkitt Lymphoma / pathology. Burkitt Lymphoma / virology. Hodgkin Disease / immunology. Hodgkin Disease / pathology. Hodgkin Disease / virology. Humans. Immunocompetence. Immunocompromised Host. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / virology

  • Genetic Alliance. consumer health - HIV.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2002 Sep 6;16(13):1803-7 [12218393.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]
  • [Cites] Haematologica. 1998 Jan;83(1):87-9 [9542326.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):16-23 [9892104.001]
  • [Cites] Am J Otolaryngol. 1999 Jan-Feb;20(1):56-8 [9950115.001]
  • [Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]
  • [Cites] Int J Dermatol. 1999 Feb;38(2):111-8 [10192159.001]
  • [Cites] Am J Surg Pathol. 1999 May;23(5):519-22 [10328082.001]
  • [Cites] Am J Surg Pathol. 1999 May;23(5):560-6 [10328088.001]
  • [Cites] Blood. 1999 Jul 1;94(1):275-82 [10381523.001]
  • [Cites] J Clin Pathol. 1999 Apr;52(4):313-6 [10474529.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] AIDS Res Hum Retroviruses. 2004 Feb;20(2):129-33 [15018699.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]
  • [Cites] Am J Hematol. 2004 May;76(1):88-91 [15114607.001]
  • [Cites] Dermatology. 2004;208(3):287-90 [15118393.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):727-38 [15151213.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1020-7 [15247554.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4227-8 [15483034.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Am J Hematol. 2004 Nov;77(3):291-5 [15495247.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] Cancer. 1988 Jun 1;61(11):2325-37 [3365660.001]
  • [Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]
  • [Cites] Am J Hematol. 1989 Nov;32(3):200-4 [2816914.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7635-9 [1652756.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):383-9 [1311023.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1768-74 [1373087.001]
  • [Cites] Am J Epidemiol. 1994 Feb 15;139(4):362-8 [8109570.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Curr Opin Oncol. 1994 Sep;6(5):492-6 [7827152.001]
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):357-63 [7872434.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] N Engl J Med. 1996 Jul 4;335(1):61-2 [8637555.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Histopathology. 1996 Feb;28(2):129-34 [8834520.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Dec 15;13(5):467-8 [8970478.001]
  • [Cites] J Am Acad Dermatol. 1999 Nov;41(5 Pt 1):722-7 [10534634.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] N Engl J Med. 2000 Mar 30;342(13):930-6 [10738051.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):647-52 [15832089.001]
  • [Cites] Leukemia. 2005 May;19(5):851-5 [15744337.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Clin Infect Dis. 2005 Oct 15;41(8):e76-9 [16163622.001]
  • [Cites] Br J Dermatol. 2005 Oct;153(4):828-32 [16181470.001]
  • [Cites] Arch Dermatol. 2005 Oct;141(10):1321-2 [16230579.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3166-74 [16014568.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):558-64 [16284532.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):438-46 [16444194.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1233-6 [16938530.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):293-302 [12604885.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] Hum Pathol. 2003 Sep;34(9):950-4 [14562294.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Arch Pathol Lab Med. 2001 Feb;125(2):282-5 [11175653.001]
  • [Cites] AIDS. 2001 Mar 30;15(5):629-33 [11317001.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):371-6 [11317081.001]
  • [Cites] Arch Pathol Lab Med. 2001 Sep;125(9):1246-8 [11520284.001]
  • [Cites] AIDS. 2001 Sep 28;15(14):1913-5 [11579268.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2339-44 [11588028.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1500-6 [11920507.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):738-41 [12033970.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • (PMID = 18042692.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 80
  • [Other-IDs] NLM/ PMC2095580
  •  go-up   go-down


85. Stevenson GT: CD38 as a therapeutic target. Mol Med; 2006 Nov-Dec;12(11-12):345-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CD38 molecule is well represented on cell surfaces in many cases of a variety of lymphoid tumors, notably multiple myeloma, AIDS-associated lymphomas, and post-transplant lymphoproliferations.
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Cell Line, Tumor. Humans. Leukemia / immunology. Lymphoma, B-Cell / immunology. Mice. Mice, SCID. Multiple Myeloma / immunology. Transplantation, Heterologous

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2001 Jan;25(1):1-12 [11137554.001]
  • [Cites] Mol Cancer Ther. 2004 Mar;3(3):345-52 [15026555.001]
  • [Cites] Scand J Immunol. 1978 Apr;7(4):297-306 [418499.001]
  • [Cites] Am J Hematol. 1990 Feb;33(2):101-9 [2301368.001]
  • [Cites] Blood. 1991 Mar 1;77(5):1071-9 [1995092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):352-6 [8380497.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1442-9 [7520771.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3017-25 [7524764.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1762-9 [15905193.001]
  • [Cites] Leuk Res. 2007 Apr;31(4):455-63 [16920192.001]
  • (PMID = 17380203.001).
  • [ISSN] 1076-1551
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; EC 3.2.2.5 / Antigens, CD38
  • [Other-IDs] NLM/ PMC1829201
  •  go-up   go-down


86. Costa H, Franco M, Hahn MD: Primary lymphoma of the central nervous system: a clinical-pathological and immunohistochemical study of ten autopsy cases. Arq Neuropsiquiatr; 2006 Dec;64(4):976-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the central nervous system: a clinical-pathological and immunohistochemical study of ten autopsy cases.
  • CONTEXT: Primary central nervous system lymphomas (PCNSL) are a rare subgroup of lymphomas generally associated with HIV and EBV.
  • METHOD: The clinical, histological and immunohistochemical data of ten cases of PCNSL, eight cases from patients with AIDS, identified among 265 autopsies of these patients were analyzed.
  • Most patients had diffuse large B cell non-Hodgkins lymphoma.
  • CONCLUSION: In the present series, PCNSL presented with focal symptoms, with unifocal or multifocal lesions, with a predominant B-cell CD20 positive phenotype, rarely associated with EBV.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adult. Autopsy. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / virology. Female. Humans. Immunohistochemistry. Lymphoma, AIDS-Related / pathology. Lymphoma, AIDS-Related / virology. Male. Middle Aged